Document and Entity Information	3 Months Ended
Document and Entity Information	Jun. 30, 2015	Jul. 31, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,726,418

Consolidated Statements of Income and Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Revenues
Net sales	$ 191,287	$ 144,541
Other revenues	845	1,161
Total revenues	192,132	145,702
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	79,896	63,836
Gross profit	112,236	81,866
Operating Expenses
Advertising and promotion	26,422	19,096
General and administrative	17,589	17,006
Depreciation and amortization	5,720	2,961
Total operating expenses	49,731	39,063
Operating income	62,505	42,803
Other (income) expense
Interest income	(27)	(32)
Interest expense	21,911	14,685
Loss on extinguishment of debt	451	0
Total other expense	22,335	14,653
Income before income taxes	40,170	28,150
Provision for income taxes	13,997	11,418
Net income	26,173	16,732
Earnings per share:
Basic (in USD per share)	$ 0.50	$ 0.32
Diluted (in USD per share)	$ 0.49	$ 0.32
Weighted average shares outstanding:
Basic (in shares)	52,548	51,956
Diluted (in shares)	52,958	52,533
Comprehensive income, net of tax:
Currency translation adjustments	(405)	2,726
Total other comprehensive income (loss)	(405)	2,726
Comprehensive income	$ 25,768	$ 19,458

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 21,598	$ 21,318
Accounts receivable, net	85,576	87,858
Inventories	74,077	74,000
Deferred income tax assets	7,918	8,097
Prepaid expenses and other current assets	11,890	10,434
Total current assets	201,059	201,707
Property and equipment, net	13,154	13,744
Goodwill	290,867	290,651
Intangible assets, net	2,129,860	2,134,700
Other long-term assets	1,562	1,165
Total Assets	2,636,502	2,641,967
Current liabilities
Current portion of long-term debt	8,525	0
Accounts payable	47,170	46,115
Accrued interest payable	9,359	11,974
Other accrued liabilities	36,738	40,948
Total current liabilities	101,792	99,037
Long-term debt
Principal amount	1,540,075	1,593,600
Less unamortized debt costs	(33,534)	(32,327)
Long-term debt, net	1,506,541	1,561,273
Deferred income tax liabilities	362,928	351,569
Other long-term liabilities	2,517	2,464
Total Liabilities	1,973,778	2,014,343
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,032 shares at June 30, 2015 and 52,562 shares at March 31, 2015	530	525
Additional paid-in capital	437,554	426,584
Treasury stock, at cost - 306 shares at June 30, 2015 and 266 shares at March 31, 2015	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(23,817)	(23,412)
Retained earnings	253,578	227,405
Total Stockholders' Equity	662,724	627,624
Total Liabilities and Stockholders' Equity	$ 2,636,502	$ 2,641,967

Consolidated Balance Sheets (Parentheticals) (USD $)	Jun. 30, 2015	Mar. 31, 2015
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	53,032,000	52,562,000
Treasury stock, shares	306,000	266,000

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Activities
Net income	$ 26,173	$ 16,732
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,720	2,961
Gain on sale of asset	(36)	0
Deferred income taxes	11,536	7,140
Amortization of debt origination costs	2,138	995
Stock-based compensation costs	3,047	1,858
Loss on extinguishment of debt	451	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,578	6,956
Inventories	(211)	1,540
Prepaid expenses and other current assets	(1,522)	(2,203)
Accounts payable	783	(3,096)
Accrued liabilities	(7,136)	(3,212)
Net cash provided by (used in) operating activities	43,521	29,671
Investing Activities
Purchases of property and equipment	(780)	(496)
Proceeds from the sale of property and equipment	344	0
Acquisition of the Hydralyte brand	0	(77,991)
Net cash used in investing activities	(436)	(78,487)
Financing Activities
Term loan repayments	(25,000)	0
Borrowings under revolving credit agreement	15,000	65,000
Repayments under revolving credit agreement	(35,000)	(30,000)
Payments of debt origination costs	(4,172)	(74)
Proceeds from exercise of stock options	6,328	1,294
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,600	950
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,171)
Net cash (used in) provided by financing activities	(42,887)	36,056
Effects of exchange rate changes on cash and cash equivalents	82	104
Increase (decrease) in cash and cash equivalents	280	(12,656)
Cash and cash equivalents - beginning of period	21,318	28,331
Cash and cash equivalents - end of period	21,598	15,675
Interest paid	22,444	13,867
Income taxes paid	$ 1,914	$ 707

Business and Basis of Presentation

3 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada), and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements.

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31^st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2016”) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three months ended June 30, 2015 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2016. These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at June 30, 2015 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Debt Origination Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as a long-term asset as deferred financing costs and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our term loan facility and the straight-line method for our revolving credit facility. During the current period, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $8.7 million for the three months ended June 30, 2015 and $7.7 million for the three months ended June 30, 2014.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In July 2015, the FASB issued Accounting Standards Update ("ASU") 2015-11, Simplifying the Measurement of Inventory. The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure in scope inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We are evaluating the impact of adopting this prospective guidance on our Consolidated Financial Statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted by the guidance, we have early adopted these provisions, as of the beginning of our first quarter of 2016. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, which are currently presented as a direct deduction from the long-term debt liability.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements.

In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items. The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements.

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In July 2015, the FASB approved a deferral of the ASU effective date from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. We are evaluating the impact of adopting this prospective guidance on our Consolidated Financial Statements.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 did not have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

3 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Acquisitions

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed the acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extended the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading brand in OTC yeast infection treatment. The acquisition also added brands to the Company's cough & cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing. Insight is primarily included in our North American OTC Healthcare segment.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed for certain immaterial items that came to our attention subsequent to the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	26,012
Inventories	23,456
Deferred income tax assets - current	1,032
Prepaids and other current assets	1,341
Property, plant and equipment	2,308
Goodwill	103,560
Intangible assets	724,374
Total assets acquired	885,590

Accounts payable	16,079
Accrued expenses	8,539
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	132,417
Total purchase price	$	753,173

Based on this analysis, we allocated $599.6 million to indefinite-lived intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at June 30, 2015 was 15.3 years.

We also recorded goodwill of $103.6 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material.

Goodwill

3 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)	North American OTC Healthcare		International OTC Healthcare			Household Cleaning		Consolidated

Balance — March 31, 2015	$	263,411	$	20,440		$	6,800	$	290,651
Adjustments	305		—			—		305
Effects of foreign currency exchange rates	—		(89		)	—		(89		)
Balance — June 30, 2015	$	263,716	$	20,351		$	6,800	$	290,867

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.6 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed by $0.3 million for certain immaterial items that came to our attention subsequent to the date of acquisition. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million, reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.

On an annual basis, during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment.

At February 28, 2015, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2015. As of June 30, 2015, there have been no triggering events that would indicate potential impairment of goodwill.

Intangible Assets

3 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:



(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Totals
Gross Carrying Amounts
Balance — March 31, 2015	$	1,873,404		$	358,066		$	2,231,470
Effects of foreign currency exchange rates	(375		)	(6		)	(381		)
Balance — June 30, 2015	1,873,029			358,060			2,231,089

Accumulated Amortization
Balance — March 31, 2015	—			96,770			96,770
Additions	—			4,460			4,460
Effects of foreign currency exchange rates	—			(1		)	(1		)
Balance — June 30, 2015	—			101,229			101,229

Intangible assets, net - June 30, 2015	$	1,873,029		$	256,831		$	2,129,860

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	231,251		$	1,908,242
International OTC Healthcare	85,766			1,594			87,360
Household Cleaning	110,272			23,986			134,258
Intangible assets, net - June 30, 2015	$	1,873,029		$	256,831		$	2,129,860

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014 we sold one of the brands that we acquired from Insight, for which we had allocated $17.7 million to the intangible assets.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.

We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. We also considered our market capitalization at February 28, 2015, which is the date of our review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

As a result of recent declines in revenues in Pediacare and in certain other brands, we continue to monitor whether events or conditions would indicate that the fair value of the intangible asset no longer exceeds the carrying value. Although we continue to believe that the fair values of our brands exceed their carrying values, sustained or significant future declines in revenue, profitability, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair value of certain brands could indicate that fair value no longer exceeds carrying value, in which case a non-cash impairment charge may be recorded in future periods.

The weighted average remaining life for finite-lived intangible assets at June 30, 2015 was approximately 14.4 years, and the amortization expense for the three months ended June 30, 2015 was $4.5 million. At June 30, 2015, finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows:



(In thousands)
Year Ending March 31,	Amount
2016 (Remaining nine months ending March 31, 2016)	$	13,401
2017	17,868
2018	17,868
2019	17,868
2020	17,868
Thereafter	171,958
	$	256,831

Long-Term Debt

3 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Long-Term Debt

2012 Senior Notes:

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that was based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

On May 8, 2015, the Borrower entered into Amendment No. 3 (the "Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provides for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million, which combined the current outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on the Term B-3 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75%, or an alternate base rate, with a floor of 1.75%, plus a margin. The maturity date of the Term B-3 Loans remains the same as the Term B-2 Loans' original maturity date of September 3, 2021.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%. For the three months ended June 30, 2015, the average interest rate on the 2012 Term Loan was 4.8%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we entered into Term Loan Amendment No. 3, we are required to make quarterly payments each equal to 0.25% of the aggregate principal amount of $852.5 million.

On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., or (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver.

On June 9, 2015, the Borrower entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provides for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date to June 9, 2020, which is five years from the effective date. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the three months ended June 30, 2015, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.3%.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Redemptions and Restrictions:

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we could have redeemed up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At June 30, 2015, we were in compliance with the covenants under our long-term indebtedness.

Effective April 1, 2015, the Company elected to change its method of presentation relating to debt issuance costs in accordance with ASU 2015-03. Prior to 2016, the Company's policy was to present these costs in other-long term assets on the balance sheet, net of accumulated amortization. Beginning in 2016, the Company has presented these fees as a direct deduction to the related long-term debt. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, which are currently presented as a direct deduction from the long-term debt liability.

At June 30, 2015, we had an aggregate $33.5 million of unamortized debt costs, the total of which is comprised of $8.3 million related to the 2012 Senior Notes, $6.0 million related to the 2013 Senior Notes and $19.2 million related to the 2012 Term Loan.

During the three months ended June 30, 2015, we had $46.1 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $63.0 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	June 30, 2015			March 31, 2015
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021.	852,500			877,500
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020.	46,100			66,100
Total long-term debt (including current portion)	1,548,600			1,593,600
Current portion of long-term debt	8,525			—
Long-term debt	1,540,075			1,593,600
Less: unamortized debt costs	(33,534		)	(32,327		)
Long-term debt, net	$	1,506,541		$	1,561,273

As of June 30, 2015, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2016 (remaining nine months ending March 31, 2016)	$	6,394
2017	8,525
2018	8,525
2019	8,525
2020	258,525
Thereafter	1,258,106
	$	1,548,600

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the Term B-3 Loans, the 2013 Senior Notes, the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At June 30, 2015 and March 31, 2015, we did not have any assets or liabilities measured in Level 1 or 3. During the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3. At June 30, 2015 and March 31, 2015, the carrying value of our 2013 Senior Notes was $400.0 million. The fair value of our 2013 Senior Notes was $398.5 million and $405.0 million at June 30, 2015 and March 31, 2015, respectively. At June 30, 2015 and March 31, 2015, the carrying value of our 2012 Senior Notes was $250.0 million. The fair value of our 2012 Senior Notes was $266.9 million and $268.1 million at June 30, 2015 and March 31, 2015, respectively. At June 30, 2015 and March 31, 2015, the carrying value of the Term B-3 Loans was $852.5 million and $877.5 million, respectively. The fair value of the Term B-3 Loans was $851.4 million and $880.5 million at June 30, 2015 and March 31, 2015, respectively. At June 30, 2015 and March 31, 2015, the carrying value of the 2012 ABL Revolver was $46.1 million and $66.1 million, respectively. The fair value of the 2012 ABL revolver was $45.9 million and $65.7 million at June 30, 2015 and March 31, 2015, respectively.

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through June 30, 2015. During the three months ended June 30, 2015 and 2014, we repurchased 39,429 shares and 33,740 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the three months ended June 30, 2015 and 2014 were at an average price of $41.66 and $33.03, respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated Other Comprehensive Loss

3 Months Ended

Jun. 30, 2015

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Loss

The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.

AOCI consisted of the following at June 30, 2015 and March 31, 2015:



	June 30,			March 31,
(In thousands)	2015			2015
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(23,817	)	$	(23,412	)
Accumulated other comprehensive loss, net of tax	$	(23,817	)	$	(23,412	)

Earnings Per Share

3 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended June 30,
(In thousands, except per share data)	2015		2014
Numerator
Net income	$	26,173	$	16,732

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,548		51,956
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	410		577
Denominator for diluted earnings per share	52,958		52,533

Earnings per Common Share:
Basic net earnings per share	$	0.50	$	0.32

Diluted net earnings per share	$	0.49	$	0.32

For the three months ended June 30, 2015 and 2014, there were 0.2 million and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

3 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock, for issuance under the Plan and increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares and extended the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three months ended June 30, 2015 and 2014, pre-tax share-based compensation costs charged against income were $3.0 million and $1.9 million, respectively, and the related income tax benefit recognized was $1.1 million and $0.7 million, respectively.

On April 22, 2015, we announced that Matthew M. Mannelly, our President and Chief Executive Officer and member of the Board of Directors, would retire effective June 1, 2015. In conjunction with his retirement, the Board of Directors accelerated the vesting of his previously unvested restricted stock units and stock options, and we recorded additional compensation expense of approximately $0.8 million associated with this acceleration. Following his retirement, and effective June 1, 2015, the Board of Directors appointed Ron Lombardi, our then current Chief Financial Officer, to succeed Mr. Mannelly as President and Chief Executive Officer and as a member of the Board of Directors. In connection with his appointment, Mr. Lombardi was granted 57,924 restricted stock units on April 22, 2015.

On May 11, 2015, the Compensation Committee of our Board of Directors granted 185,904 restricted stock units and stock options to acquire 186,302 shares of our common stock to certain executive officers and employees under the Plan. Of those grants, 163,404 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 22,500 restricted stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $41.44 per share, which is equal to the closing price of our common stock on the date of grant.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units, unless otherwise accelerated by the Compensation Committee of the Board of Directors. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

The fair value of the restricted stock units is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value during the three months ended June 30, 2015 and 2014 was $41.85 and $33.50, respectively.

A summary of the Company's restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Three months ended June 30, 2014
Vested and nonvested at March 31, 2014	437.5		$	16.76
Granted	96.6		33.50
Vested and issued	(93.7	)	15.12
Forfeited	(14.4	)	20.78
Vested and nonvested at June 30, 2014	426.0		20.78
Vested at June 30, 2014	69.6		9.34

Three months ended June 30, 2015
Vested and nonvested at March 31, 2015	362.3		$	22.74
Granted	243.8		41.85
Vested and issued	(138.9	)	19.35
Forfeited	(1.4	)	33.50
Vested and nonvested at June 30, 2015	465.8		33.72
Vested at June 30, 2015	76.6		11.62

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

The weighted-average grant-date fair values of the options granted during the three months ended June 30, 2015 and 2014 was $16.95 and $15.93, respectively.



	Three Months Ended June 30,
	2015			2014
Expected volatility	40.2		%	47.3		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	1.7		%	2.2		%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Three months ended June 30, 2014:
Outstanding at March 31, 2014	994.9		$	15.24
Granted	307.5		33.50
Exercised	(93.8	)	13.80
Forfeited or expired	(31.6	)	25.49
Outstanding at June 30, 2014	1,177.0		19.85		7.8	$	16,527
Exercisable at June 30, 2014	375.1		15.23		7.3	6,998

Three months ended June 30, 2015:
Outstanding at March 31, 2015	871.2		$	23.40
Granted	186.3		41.44
Exercised	(330.4	)	19.15
Forfeited or expired	(0.9	)	33.50
Outstanding at June 30, 2015	726.2		29.95		8.3	$	11,830
Exercisable at June 30, 2015	322.5		21.54		7.2	7,966

The aggregate intrinsic value of options exercised in the three months ended June 30, 2015 was $8.1 million.

At June 30, 2015, there were $14.5 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.3 years. The total fair value of options and restricted shares vested during the three months ended June 30, 2015 and 2014 was $6.2 million and $4.7 million, respectively. For the three months ended June 30, 2015 and 2014, cash received from the exercise of stock options was $6.3 million and $1.3 million, respectively, and we realized $1.0 million and $1.0 million, respectively, in tax benefits from the tax deductions resulting from these option exercises. At June 30, 2015, there were 2.6 million shares available for issuance under the Plan.

Income Taxes	3 Months Ended
Income Taxes	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 34.8% and 40.6% for the three months ended June 30, 2015 and June 30, 2014, respectively. The decrease in the effective tax rate for the three months ended June 30, 2015 was primarily due to the impact of certain non-deductible items related to acquisitions in the prior year period and to favorable tax deductions related to stock options and equity awards that were realized in the current year period. At June 30, 2015, wholly-owned subsidiaries of the Company had net operating loss carryforwards of approximately $53.0 million, which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020. The net operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire. The balance in our uncertain tax liability was $3.4 million at June 30, 2015 and March 31, 2015. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments and Contingencies

3 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our financial condition or results of operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases as of June 30, 2015 ^(a):



(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2016 (Remaining nine months ending March 31, 2016)	$	1,312	$	228	$	1,540
2017	1,861		77		1,938
2018	1,871		—		1,871
2019	1,864		—		1,864
2020	1,695		—		1,695
Thereafter	770		—		770
	$	9,373	$	305	$	9,678

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.3 million due in the future

under noncancelable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



(In thousands)	June 30, 2015			March 31, 2015
Minimum lease payments	$	9,678		$	9,957
Less: Sublease rentals	(1,342		)	(1,401		)
	$	8,336		$	8,556

Rent expense for the three months ended June 30, 2015 and 2014 was $0.4 million and $0.4 million, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,	Amount
2016 (Remaining nine months ending March 31, 2016)	803
2017	1,044
2018	1,013
2019	982
2020	560
Thereafter	—
	$	4,402

Concentrations of Risk	3 Months Ended
Concentrations of Risk	Jun. 30, 2015
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores. During the three months ended June 30, 2015, approximately 43.9% of our total revenues were derived from our five top selling brands. During the three months ended June 30, 2014, approximately 42.0% of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 19.9% of our gross revenues for the three months ended June 30, 2015, and approximately 19.2% of our gross revenues for the three months ended June 30, 2014. Our next largest customer accounted for approximately 9.4% of gross revenues for the three months ended June 30, 2015. At June 30, 2015, approximately 21.8% of accounts receivable were owed by Walmart. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At June 30, 2015, we had relationships with 98 third-party manufacturers. Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 83.9% of gross sales for the three months ended June 30, 2015. At June 30, 2014, we had relationships with 61 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 84.5% of gross sales for the three months ended June 30, 2014. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach agreement which could have a material adverse effect on our business.

Business Segments

3 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our reportable segments.



	Three Months Ended June 30, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	156,339		$	14,209	$	21,467	$	192,015
Elimination of intersegment revenues	(728		)	—		—		(728		)
Third-party segment revenues	155,611			14,209		21,467		191,287
Other revenues	40			—		805		845
Total segment revenues	155,651			14,209		22,272		192,132
Cost of sales	58,126			5,290		16,480		79,896
Gross profit	97,525			8,919		5,792		112,236
Advertising and promotion	23,195			2,723		504		26,422
Contribution margin	$	74,330		$	6,196	$	5,288	85,814
Other operating expenses								23,309
Operating income								62,505
Other expense								22,335
Income before income taxes								40,170
Provision for income taxes								13,997
Net income								$	26,173



	Three Months Ended June 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	110,973		$	13,692	$	20,593	$	145,258
Elimination of intersegment revenues	(717		)	—		—		(717		)
Third-party segment revenues	110,256			13,692		20,593		144,541
Other revenues	177			35		949		1,161
Total segment revenues	110,433			13,727		21,542		145,702
Cost of sales	42,340			5,078		16,418		63,836
Gross profit	68,093			8,649		5,124		81,866
Advertising and promotion	16,353			2,339		404		19,096
Contribution margin	$	51,740		$	6,310	$	4,720	62,770
Other operating expenses								19,967
Operating income								42,803
Other expense								14,653
Income before income taxes								28,150
Provision for income taxes								11,418
Net income								$	16,732

The tables below summarize information about our segment revenues from similar product groups.



	Three Months Ended June 30, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	26,848	$	530	$	—	$	27,378
Cough & Cold	19,759		4,506		—		24,265
Women's Health	32,908		700		—		33,608
Gastrointestinal	20,320		3,808		—		24,128
Eye & Ear Care	24,332		3,930		—		28,262
Dermatologicals	20,095		534		—		20,629
Oral Care	9,977		194		—		10,171
Other OTC	1,412		7		—		1,419
Household Cleaning	—		—		22,272		22,272
Total segment revenues	$	155,651	$	14,209	$	22,272	$	192,132



	Three Months Ended June 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	25,031	$	665	$	—	$	25,696
Cough & Cold	20,043		4,798		—		24,841
Women's Health	368		518		—		886
Gastrointestinal	20,638		2,497		—		23,135
Eye & Ear Care	20,725		4,642		—		25,367
Dermatologicals	12,260		542		—		12,802
Oral Care	10,187		62		—		10,249
Other OTC	1,181		3		—		1,184
Household Cleaning	—		—		21,542		21,542
Total segment revenues	$	110,433	$	13,727	$	21,542	$	145,702

During the three months ended June 30, 2015 and June 30, 2014, approximately 87.3% and 84.5%, respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended June 30, 2015, our Canada and Australia sales accounted for approximately 5.1% and 5.7%, respectively, of our total segment revenues, while during the three months ended June 30, 2014, approximately 5.6% and 5.2%, respectively, of our total segment revenues was attributable to sales to Canada and Australia.

At June 30, 2015, approximately 95.6% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.4% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,716	$	20,351	$	6,800	$	290,867

Intangible assets
Indefinite-lived	1,676,991		85,766		110,272		1,873,029
Finite-lived	231,251		1,594		23,986		256,831
Intangible assets, net	1,908,242		87,360		134,258		2,129,860
Total	$	2,171,958	$	107,711	$	141,058	$	2,420,727

Condensed Consolidating Financial Statements

3 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC and Practical Health Products, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of June 30, 2015 and March 31, 2015, Condensed Consolidating Statements of Income and Comprehensive Income for the three months ended June 30, 2015 and 2014, and Condensed Consolidating Statements of Cash Flows for the three months ended June 30, 2015 and 2014. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the Issuer or the Borrower,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended June 30, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	27,883		$	152,524		$	11,608		$	(728	)	$	191,287
Other revenues	—			96			819			498			(568		)	845
Total revenues	—			27,979			153,343			12,106			(1,296		)	192,132

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,441			66,378			4,408			(1,331		)	79,896
Gross profit	—			17,538			86,965			7,698			35			112,236

Operating Expenses
Advertising and promotion	—			2,517			21,228			2,677			—			26,422
General and administrative	1,315			2,555			11,951			1,768			—			17,589
Depreciation and amortization	989			146			4,445			140			—			5,720
Total operating expenses	2,304			5,218			37,624			4,585			—			49,731
Operating income (loss)	(2,304		)	12,320			49,341			3,113			35			62,505

Other (income) expense
Interest income	(12,049		)	(21,408		)	(1,220		)	(112		)	34,762			(27		)
Interest expense	8,490			21,908			25,055			1,220			(34,762		)	21,911
Loss on extinguishment of debt	—			451			—			—			—			451
Equity in (income) loss of subsidiaries	(25,306		)	(16,955		)	(1,450		)	—			43,711			—
Total other (income) expense	(28,865		)	(16,004		)	22,385			1,108			43,711			22,335
Income (loss) before income taxes	26,561			28,324			26,956			2,005			(43,676		)	40,170
Provision for income taxes	388			4,025			9,029			555			—			13,997
Net income (loss)	$	26,173		$	24,299		$	17,927		$	1,450		$	(43,676	)	$	26,173

Comprehensive income, net of tax:
Currency translation adjustments	(405		)	(405		)	(405		)	(405		)	1,215			(405		)
Total other comprehensive income (loss)	(405		)	(405		)	(405		)	(405		)	1,215			(405		)
Comprehensive income (loss)	$	25,768		$	23,894		$	17,522		$	1,045		$	(42,461	)	$	25,768

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended June 30, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,410		$	108,898		$	10,951		$	(718	)	$	144,541
Other revenues	—			130			1,099			402			(470		)	1,161
Total revenues	—			25,540			109,997			11,353			(1,188		)	145,702

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,448			50,515			4,023			(150		)	63,836
Gross profit	—			16,092			59,482			7,330			(1,038		)	81,866

Operating Expenses
Advertising and promotion	—			2,689			14,066			2,341			—			19,096
General and administrative	1,145			2,473			8,990			4,398			—			17,006
Depreciation and amortization	642			145			2,089			85			—			2,961
Total operating expenses	1,787			5,307			25,145			6,824			—			39,063
Operating income (loss)	(1,787		)	10,785			34,337			506			(1,038		)	42,803

Other (income) expense
Interest income	(12,133		)	(14,225		)	(762		)	(29		)	27,117			(32		)
Interest expense	8,548			14,685			17,805			764			(27,117		)	14,685
Equity in (income) loss of subsidiaries	(15,679		)	(10,898		)	959			—			25,618			—
Total other (income) expense	(19,264		)	(10,438		)	18,002			735			25,618			14,653
Income (loss) before income taxes	17,477			21,223			16,335			(229		)	(26,656		)	28,150
Provision for income taxes	745			3,717			6,226			730			—			11,418
Net income (loss)	$	16,732		$	17,506		$	10,109		$	(959	)	$	(26,656	)	$	16,732

Comprehensive income, net of tax:
Currency translation adjustments	2,726			2,726			2,726			2,726			(8,178		)	2,726
Total other comprehensive income (loss)	2,726			2,726			2,726			2,726			(8,178		)	2,726
Comprehensive income (loss)	$	19,458		$	20,232		$	12,835		$	1,767		$	(34,834	)	$	19,458

Condensed Consolidating Balance Sheet

June 30, 2015




(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	10,832		$	—		$	—		$	10,766		$	—		$	21,598
Accounts receivable, net	—			11,368			66,016			8,192			—			85,576
Inventories	—			7,492			61,651			6,045			(1,111		)	74,077
Deferred income tax assets	311			705			6,567			335			—			7,918
Prepaid expenses and other current assets	7,883			243			3,016			748			—			11,890
Total current assets	19,026			19,808			137,250			26,086			(1,111		)	201,059

Property and equipment, net	10,301			163			2,291			399			—			13,154
Goodwill	—			66,007			204,510			20,350			—			290,867
Intangible assets, net	—			192,191			1,850,501			87,168			—			2,129,860
Other long-term assets	—			1,562			—			—			—			1,562
Intercompany receivables	1,215,771			2,572,637			695,741			9,174			(4,493,323		)	—
Investment in subsidiary	1,569,115			1,245,085			67,970			—			(2,882,170		)	—
Total Assets	$	2,814,213		$	4,097,453		$	2,958,263		$	143,177		$	(7,376,604	)	$	2,636,502

Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt	$	—		$	8,525		$	—		$	—		$	—		$	8,525
Accounts payable	2,846			6,504			33,871			3,949			—			47,170
Accrued interest payable	—			9,359			—			—			—			9,359
Other accrued liabilities	4,710			1,400			27,116			3,512			—			36,738
Total current liabilities	7,556			25,788			60,987			7,461			—			101,792

Long-term debt
Principal amount	—			1,540,075			—			—			—			1,540,075
Less unamortized debt costs	—			(33,534		)	—			—			—			(33,534		)
Long-term debt, net	—			1,506,541			—			—			—			1,506,541

Deferred income tax liabilities	—			59,464			303,440			24			—			362,928
Other long-term liabilities	—			—			2,333			184			—			2,517
Intercompany payables	2,143,933			1,003,970			1,275,240			70,180			(4,493,323		)	—
Total Liabilities	2,151,489			2,595,763			1,642,000			77,849			(4,493,323		)	1,973,778

Stockholders' Equity
Common stock	530			—			—			—			—			530
Additional paid-in capital	437,554			1,280,948			1,131,578			74,031			(2,486,557		)	437,554
Treasury stock, at cost	(5,121		)	—			—			—			—			(5,121		)
Accumulated other comprehensive income (loss), net of tax	(23,817		)	(23,817		)	(23,817		)	(23,817		)	71,451			(23,817		)
Retained earnings (accumulated deficit)	253,578			244,559			208,502			15,114			(468,175		)	253,578
Total Stockholders' Equity	662,724			1,501,690			1,316,263			65,328			(2,883,281		)	662,724
Total Liabilities and Stockholders' Equity	$	2,814,213		$	4,097,453		$	2,958,263		$	143,177		$	(7,376,604	)	$	2,636,502

Condensed Consolidating Balance Sheet

March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318
Accounts receivable, net	—			14,539			66,523			6,796			—			87,858
Inventories	—			8,667			60,297			6,182			(1,146		)	74,000
Deferred income tax assets	452			674			6,497			474			—			8,097
Prepaid expenses and other current assets	5,731			141			3,804			758			—			10,434
Total current assets	17,570			24,021			137,121			24,141			(1,146		)	201,707

Property and equipment, net	10,726			175			2,207			636			—			13,744
Goodwill	—			66,007			204,205			20,439			—			290,651
Intangible assets, net	—			192,325			1,854,798			87,577			—			2,134,700
Other long-term assets	—			1,165			—			—			—			1,165
Intercompany receivables	1,210,017			2,607,054			668,169			8,764			(4,494,004		)	—
Investment in subsidiary	1,545,575			1,228,535			65,564			—			(2,839,674		)	—
Total Assets	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,959		$	6,829		$	32,898		$	4,429		$	—		$	46,115
Accrued interest payable	—			11,974			—			—			—			11,974
Other accrued liabilities	10,378			1,153			25,795			3,622			—			40,948
Total current liabilities	12,337			19,956			58,693			8,051			—			99,037

Long-term debt
Principal amount	—			1,593,600			—			—			—			1,593,600
Less unamortized debt costs	—			(32,327		)	—			—			—			(32,327		)
Long-term debt, net	—			1,561,273			—			—			—			1,561,273

Deferred income tax liabilities	—			59,038			292,504			27			—			351,569
Other long-term liabilities	—			—			2,293			171			—			2,464
Intercompany payables	2,143,927			1,001,219			1,279,833			69,025			(4,494,004		)	—
Total Liabilities	2,156,264			2,641,486			1,633,323			77,274			(4,494,004		)	2,014,343

Stockholders' Equity
Common stock	525			—			—			—			—			525
Additional paid-in capital	426,584			1,280,948			1,131,578			74,031			(2,486,557		)	426,584
Treasury stock, at cost	(3,478		)	—			—			—			—			(3,478		)
Accumulated other comprehensive income (loss), net of tax	(23,412		)	(23,412		)	(23,412		)	(23,412		)	70,236			(23,412		)
Retained earnings (accumulated deficit)	227,405			220,260			190,575			13,664			(424,499		)	227,405
Total Stockholders' Equity	627,624			1,477,796			1,298,741			64,283			(2,840,820		)	627,624
Total Liabilities and Stockholders' Equity	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Condensed Consolidating Statement of Cash Flows

Three Months Ended June 30, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	26,173		$	24,299		$	17,927		$	1,450		$	(43,676	)	$	26,173
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	989			146			4,445			140			—			5,720
Gain on sale of asset	—			—			—			(36		)	—			(36		)
Deferred income taxes	141			395			10,866			134			—			11,536
Amortization of debt origination costs	—			2,138			—			—			—			2,138
Stock-based compensation costs	3,047			—			—			—			—			3,047
Loss on extinguishment of debt	—			451			—			—			—			451
Equity in income of subsidiaries	(25,306		)	(16,955		)	(1,450		)	—			43,711			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			3,171			735			(1,328		)	—			2,578
Inventories	—			1,175			(1,457		)	106			(35		)	(211		)
Prepaid expenses and other current assets	(2,152		)	(102		)	722			10			—			(1,522		)
Accounts payable	861			(325		)	880			(633		)	—			783
Accrued liabilities	(5,668		)	(2,368		)	975			(75		)	—			(7,136		)
Net cash provided by (used in) operating activities	(1,915		)	12,025			33,643			(232		)	—			43,521

Investing Activities
Purchases of property and equipment	(648		)	—			(27		)	(105		)	—			(780		)
Proceeds from the sale of property and equipment	—			—			—			344			—			344
Net cash (used in) provided by investing activities	(648		)	—			(27		)	239			—			(436		)

Financing Activities
Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
Borrowings under revolving credit agreement	—			15,000			—			—			—			15,000
Repayments under revolving credit agreement	—			(35,000		)	—			—			—			(35,000		)
Payments of debt origination costs	—			(4,172		)	—			—			—			(4,172		)
Proceeds from exercise of stock options	6,328			—			—			—			—			6,328
Proceeds from restricted stock exercises	544			—			—			—			—			544
Excess tax benefits from share-based awards	1,600			—			—			—			—			1,600
Fair value of shares surrendered as payment of tax withholding	(2,187		)	—			—			—			—			(2,187		)
Intercompany activity, net	(4,277		)	37,147			(33,616		)	746			—			—
Net cash provided by (used in) financing activities	2,008			(12,025		)	(33,616		)	746			—			(42,887		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			82			—			82
(Decrease) increase in cash and cash equivalents	(555		)	—			—			835			—			280
Cash and cash equivalents - beginning of period	11,387			—			—			9,931			—			21,318
Cash and cash equivalents - end of period	$	10,832		$	—		$	—		$	10,766		$	—		$	21,598

Condensed Consolidating Statement of Cash Flows

Three Months Ended June 30, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	16,732		$	17,506		$	10,109		$	(959	)	$	(26,656	)	$	16,732
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	642			145			2,089			85			—			2,961
Deferred income taxes	(1		)	892			6,330			(81		)	—			7,140
Amortization of debt origination costs	—			995			—			—			—			995
Stock-based compensation costs	1,858			—			—			—			—			1,858
Equity in income of subsidiaries	(15,679		)	(10,898		)	959			—			25,618			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	467			(130		)	8,941			(2,322		)	—			6,956
Inventories	—			3,288			(2,822		)	36			1,038			1,540
Prepaid expenses and other current assets	947			(920		)	(1,706		)	(524		)	—			(2,203		)
Accounts payable	(936		)	(916		)	(2,918		)	1,674			—			(3,096		)
Accrued liabilities	(4,800		)	4,733			(5,663		)	2,518			—			(3,212		)
Net cash provided by (used in) operating activities	(770		)	14,695			15,319			427			—			29,671

Investing Activities
Purchases of property and equipment	(385		)	—			(11		)	(100		)	—			(496		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(77,991		)	—			77,991			—			—
Net cash used in investing activities	(385		)	(77,991		)	(11		)	(100		)	—			(78,487		)

Financing Activities
Borrowings under revolving credit agreement	—			65,000			—			—			—			65,000
Repayments under revolving credit agreement	—			(30,000		)	—			—			—			(30,000		)
Payment of debt origination costs	—			(74		)	—			—			—			(74		)
Proceeds from exercise of stock options	1,294			—			—			—			—			1,294
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	950			—			—			—			—			950
Fair value of shares surrendered as payment of tax withholding	(1,171		)	—			—			—			—			(1,171		)
Intercompany activity, net	(13,700		)	28,370			(15,308		)	638			—			—
Net cash provided by (used in) financing activities	(12,570		)	63,296			(15,308		)	638			—			36,056

Effect of exchange rate changes on cash and cash equivalents	—			—			—			104			—			104
(Decrease) increase in cash and cash equivalents	(13,725		)	—			—			1,069			—			(12,656		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	10,919		$	—		$	—		$	4,756		$	—		$	15,675

Business and Basis of Presentation (Policies)

3 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Debt Origination Costs

Revenue Recognition

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Stock-based Compensation

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Business and Basis of Presentation (Tables)

3 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Property and equipment consist of the following:



(In thousands)	June 30, 2015			March 31, 2015
Components of Property and Equipment
Machinery	$	3,943		$	4,743
Computer equipment	12,509			11,339
Furniture and fixtures	2,371			2,484
Leasehold improvements	7,296			7,134
	26,119			25,700
Accumulated depreciation	(12,965		)	(11,956		)
Property and equipment, net	$	13,154		$	13,744

Acquisitions (Tables)

3 Months Ended

Jun. 30, 2015

Insight Pharmaceuticals

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	26,012
Inventories	23,456
Deferred income tax assets - current	1,032
Prepaids and other current assets	1,341
Property, plant and equipment	2,308
Goodwill	103,560
Intangible assets	724,374
Total assets acquired	885,590

Accounts payable	16,079
Accrued expenses	8,539
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	132,417
Total purchase price	$	753,173

Hydralyte

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Property and Equipment (Tables)

3 Months Ended

Jun. 30, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Property and equipment consist of the following:



(In thousands)	June 30, 2015			March 31, 2015
Components of Property and Equipment
Machinery	$	3,943		$	4,743
Computer equipment	12,509			11,339
Furniture and fixtures	2,371			2,484
Leasehold improvements	7,296			7,134
	26,119			25,700
Accumulated depreciation	(12,965		)	(11,956		)
Property and equipment, net	$	13,154		$	13,744

Intangible Assets (Tables)

3 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:



(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Totals
Gross Carrying Amounts
Balance — March 31, 2015	$	1,873,404		$	358,066		$	2,231,470
Effects of foreign currency exchange rates	(375		)	(6		)	(381		)
Balance — June 30, 2015	1,873,029			358,060			2,231,089

Accumulated Amortization
Balance — March 31, 2015	—			96,770			96,770
Additions	—			4,460			4,460
Effects of foreign currency exchange rates	—			(1		)	(1		)
Balance — June 30, 2015	—			101,229			101,229

Intangible assets, net - June 30, 2015	$	1,873,029		$	256,831		$	2,129,860

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	231,251		$	1,908,242
International OTC Healthcare	85,766			1,594			87,360
Household Cleaning	110,272			23,986			134,258
Intangible assets, net - June 30, 2015	$	1,873,029		$	256,831		$	2,129,860

Schedule of Expected Amortization Expense

At June 30, 2015, finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows:



(In thousands)
Year Ending March 31,	Amount
2016 (Remaining nine months ending March 31, 2016)	$	13,401
2017	17,868
2018	17,868
2019	17,868
2020	17,868
Thereafter	171,958
	$	256,831

Long-Term Debt (Tables)

3 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	June 30, 2015			March 31, 2015
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021.	852,500			877,500
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020.	46,100			66,100
Total long-term debt (including current portion)	1,548,600			1,593,600
Current portion of long-term debt	8,525			—
Long-term debt	1,540,075			1,593,600
Less: unamortized debt costs	(33,534		)	(32,327		)
Long-term debt, net	$	1,506,541		$	1,561,273

Aggregate Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2016 (remaining nine months ending March 31, 2016)	$	6,394
2017	8,525
2018	8,525
2019	8,525
2020	258,525
Thereafter	1,258,106
	$	1,548,600

Accumulated Other Comprehensive Loss (Tables)

3 Months Ended

Jun. 30, 2015

Accumulated Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income

AOCI consisted of the following at June 30, 2015 and March 31, 2015:



	June 30,			March 31,
(In thousands)	2015			2015
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(23,817	)	$	(23,412	)
Accumulated other comprehensive loss, net of tax	$	(23,817	)	$	(23,412	)

Earnings Per Share (Tables)

3 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended June 30,
(In thousands, except per share data)	2015		2014
Numerator
Net income	$	26,173	$	16,732

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,548		51,956
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	410		577
Denominator for diluted earnings per share	52,958		52,533

Earnings per Common Share:
Basic net earnings per share	$	0.50	$	0.32

Diluted net earnings per share	$	0.49	$	0.32

Share-Based Compensation (Tables)

3 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company's restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Three months ended June 30, 2014
Vested and nonvested at March 31, 2014	437.5		$	16.76
Granted	96.6		33.50
Vested and issued	(93.7	)	15.12
Forfeited	(14.4	)	20.78
Vested and nonvested at June 30, 2014	426.0		20.78
Vested at June 30, 2014	69.6		9.34

Three months ended June 30, 2015
Vested and nonvested at March 31, 2015	362.3		$	22.74
Granted	243.8		41.85
Vested and issued	(138.9	)	19.35
Forfeited	(1.4	)	33.50
Vested and nonvested at June 30, 2015	465.8		33.72
Vested at June 30, 2015	76.6		11.62

Stock Options, Valuation Assumptions



	Three Months Ended June 30,
	2015			2014
Expected volatility	40.2		%	47.3		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	1.7		%	2.2		%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Three months ended June 30, 2014:
Outstanding at March 31, 2014	994.9		$	15.24
Granted	307.5		33.50
Exercised	(93.8	)	13.80
Forfeited or expired	(31.6	)	25.49
Outstanding at June 30, 2014	1,177.0		19.85		7.8	$	16,527
Exercisable at June 30, 2014	375.1		15.23		7.3	6,998

Three months ended June 30, 2015:
Outstanding at March 31, 2015	871.2		$	23.40
Granted	186.3		41.44
Exercised	(330.4	)	19.15
Forfeited or expired	(0.9	)	33.50
Outstanding at June 30, 2015	726.2		29.95		8.3	$	11,830
Exercisable at June 30, 2015	322.5		21.54		7.2	7,966

Commitments and Contingencies (Tables)

3 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases as of June 30, 2015 ^(a):



(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2016 (Remaining nine months ending March 31, 2016)	$	1,312	$	228	$	1,540
2017	1,861		77		1,938
2018	1,871		—		1,871
2019	1,864		—		1,864
2020	1,695		—		1,695
Thereafter	770		—		770
	$	9,373	$	305	$	9,678

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.3 million due in the future

under noncancelable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



(In thousands)	June 30, 2015			March 31, 2015
Minimum lease payments	$	9,678		$	9,957
Less: Sublease rentals	(1,342		)	(1,401		)
	$	8,336		$	8,556

Unrecorded Unconditional Purchase Obligations Disclosure

Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,	Amount
2016 (Remaining nine months ending March 31, 2016)	803
2017	1,044
2018	1,013
2019	982
2020	560
Thereafter	—
	$	4,402

Business Segments (Tables)

3 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our reportable segments.



	Three Months Ended June 30, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	156,339		$	14,209	$	21,467	$	192,015
Elimination of intersegment revenues	(728		)	—		—		(728		)
Third-party segment revenues	155,611			14,209		21,467		191,287
Other revenues	40			—		805		845
Total segment revenues	155,651			14,209		22,272		192,132
Cost of sales	58,126			5,290		16,480		79,896
Gross profit	97,525			8,919		5,792		112,236
Advertising and promotion	23,195			2,723		504		26,422
Contribution margin	$	74,330		$	6,196	$	5,288	85,814
Other operating expenses								23,309
Operating income								62,505
Other expense								22,335
Income before income taxes								40,170
Provision for income taxes								13,997
Net income								$	26,173



	Three Months Ended June 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	110,973		$	13,692	$	20,593	$	145,258
Elimination of intersegment revenues	(717		)	—		—		(717		)
Third-party segment revenues	110,256			13,692		20,593		144,541
Other revenues	177			35		949		1,161
Total segment revenues	110,433			13,727		21,542		145,702
Cost of sales	42,340			5,078		16,418		63,836
Gross profit	68,093			8,649		5,124		81,866
Advertising and promotion	16,353			2,339		404		19,096
Contribution margin	$	51,740		$	6,310	$	4,720	62,770
Other operating expenses								19,967
Operating income								42,803
Other expense								14,653
Income before income taxes								28,150
Provision for income taxes								11,418
Net income								$	16,732

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.



	Three Months Ended June 30, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	26,848	$	530	$	—	$	27,378
Cough & Cold	19,759		4,506		—		24,265
Women's Health	32,908		700		—		33,608
Gastrointestinal	20,320		3,808		—		24,128
Eye & Ear Care	24,332		3,930		—		28,262
Dermatologicals	20,095		534		—		20,629
Oral Care	9,977		194		—		10,171
Other OTC	1,412		7		—		1,419
Household Cleaning	—		—		22,272		22,272
Total segment revenues	$	155,651	$	14,209	$	22,272	$	192,132



	Three Months Ended June 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	25,031	$	665	$	—	$	25,696
Cough & Cold	20,043		4,798		—		24,841
Women's Health	368		518		—		886
Gastrointestinal	20,638		2,497		—		23,135
Eye & Ear Care	20,725		4,642		—		25,367
Dermatologicals	12,260		542		—		12,802
Oral Care	10,187		62		—		10,249
Other OTC	1,181		3		—		1,184
Household Cleaning	—		—		21,542		21,542
Total segment revenues	$	110,433	$	13,727	$	21,542	$	145,702

Allocation of Long-Term Assets to Segments



(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,716	$	20,351	$	6,800	$	290,867

Intangible assets
Indefinite-lived	1,676,991		85,766		110,272		1,873,029
Finite-lived	231,251		1,594		23,986		256,831
Intangible assets, net	1,908,242		87,360		134,258		2,129,860
Total	$	2,171,958	$	107,711	$	141,058	$	2,420,727

Condensed Consolidating Financial Statements (Tables)

3 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended June 30, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	27,883		$	152,524		$	11,608		$	(728	)	$	191,287
Other revenues	—			96			819			498			(568		)	845
Total revenues	—			27,979			153,343			12,106			(1,296		)	192,132

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,441			66,378			4,408			(1,331		)	79,896
Gross profit	—			17,538			86,965			7,698			35			112,236

Operating Expenses
Advertising and promotion	—			2,517			21,228			2,677			—			26,422
General and administrative	1,315			2,555			11,951			1,768			—			17,589
Depreciation and amortization	989			146			4,445			140			—			5,720
Total operating expenses	2,304			5,218			37,624			4,585			—			49,731
Operating income (loss)	(2,304		)	12,320			49,341			3,113			35			62,505

Other (income) expense
Interest income	(12,049		)	(21,408		)	(1,220		)	(112		)	34,762			(27		)
Interest expense	8,490			21,908			25,055			1,220			(34,762		)	21,911
Loss on extinguishment of debt	—			451			—			—			—			451
Equity in (income) loss of subsidiaries	(25,306		)	(16,955		)	(1,450		)	—			43,711			—
Total other (income) expense	(28,865		)	(16,004		)	22,385			1,108			43,711			22,335
Income (loss) before income taxes	26,561			28,324			26,956			2,005			(43,676		)	40,170
Provision for income taxes	388			4,025			9,029			555			—			13,997
Net income (loss)	$	26,173		$	24,299		$	17,927		$	1,450		$	(43,676	)	$	26,173

Comprehensive income, net of tax:
Currency translation adjustments	(405		)	(405		)	(405		)	(405		)	1,215			(405		)
Total other comprehensive income (loss)	(405		)	(405		)	(405		)	(405		)	1,215			(405		)
Comprehensive income (loss)	$	25,768		$	23,894		$	17,522		$	1,045		$	(42,461	)	$	25,768

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended June 30, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,410		$	108,898		$	10,951		$	(718	)	$	144,541
Other revenues	—			130			1,099			402			(470		)	1,161
Total revenues	—			25,540			109,997			11,353			(1,188		)	145,702

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,448			50,515			4,023			(150		)	63,836
Gross profit	—			16,092			59,482			7,330			(1,038		)	81,866

Operating Expenses
Advertising and promotion	—			2,689			14,066			2,341			—			19,096
General and administrative	1,145			2,473			8,990			4,398			—			17,006
Depreciation and amortization	642			145			2,089			85			—			2,961
Total operating expenses	1,787			5,307			25,145			6,824			—			39,063
Operating income (loss)	(1,787		)	10,785			34,337			506			(1,038		)	42,803

Other (income) expense
Interest income	(12,133		)	(14,225		)	(762		)	(29		)	27,117			(32		)
Interest expense	8,548			14,685			17,805			764			(27,117		)	14,685
Equity in (income) loss of subsidiaries	(15,679		)	(10,898		)	959			—			25,618			—
Total other (income) expense	(19,264		)	(10,438		)	18,002			735			25,618			14,653
Income (loss) before income taxes	17,477			21,223			16,335			(229		)	(26,656		)	28,150
Provision for income taxes	745			3,717			6,226			730			—			11,418
Net income (loss)	$	16,732		$	17,506		$	10,109		$	(959	)	$	(26,656	)	$	16,732

Comprehensive income, net of tax:
Currency translation adjustments	2,726			2,726			2,726			2,726			(8,178		)	2,726
Total other comprehensive income (loss)	2,726			2,726			2,726			2,726			(8,178		)	2,726
Comprehensive income (loss)	$	19,458		$	20,232		$	12,835		$	1,767		$	(34,834	)	$	19,458

Condensed Consolidating Balance Sheet

June 30, 2015




(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	10,832		$	—		$	—		$	10,766		$	—		$	21,598
Accounts receivable, net	—			11,368			66,016			8,192			—			85,576
Inventories	—			7,492			61,651			6,045			(1,111		)	74,077
Deferred income tax assets	311			705			6,567			335			—			7,918
Prepaid expenses and other current assets	7,883			243			3,016			748			—			11,890
Total current assets	19,026			19,808			137,250			26,086			(1,111		)	201,059

Property and equipment, net	10,301			163			2,291			399			—			13,154
Goodwill	—			66,007			204,510			20,350			—			290,867
Intangible assets, net	—			192,191			1,850,501			87,168			—			2,129,860
Other long-term assets	—			1,562			—			—			—			1,562
Intercompany receivables	1,215,771			2,572,637			695,741			9,174			(4,493,323		)	—
Investment in subsidiary	1,569,115			1,245,085			67,970			—			(2,882,170		)	—
Total Assets	$	2,814,213		$	4,097,453		$	2,958,263		$	143,177		$	(7,376,604	)	$	2,636,502

Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt	$	—		$	8,525		$	—		$	—		$	—		$	8,525
Accounts payable	2,846			6,504			33,871			3,949			—			47,170
Accrued interest payable	—			9,359			—			—			—			9,359
Other accrued liabilities	4,710			1,400			27,116			3,512			—			36,738
Total current liabilities	7,556			25,788			60,987			7,461			—			101,792

Long-term debt
Principal amount	—			1,540,075			—			—			—			1,540,075
Less unamortized debt costs	—			(33,534		)	—			—			—			(33,534		)
Long-term debt, net	—			1,506,541			—			—			—			1,506,541

Deferred income tax liabilities	—			59,464			303,440			24			—			362,928
Other long-term liabilities	—			—			2,333			184			—			2,517
Intercompany payables	2,143,933			1,003,970			1,275,240			70,180			(4,493,323		)	—
Total Liabilities	2,151,489			2,595,763			1,642,000			77,849			(4,493,323		)	1,973,778

Stockholders' Equity
Common stock	530			—			—			—			—			530
Additional paid-in capital	437,554			1,280,948			1,131,578			74,031			(2,486,557		)	437,554
Treasury stock, at cost	(5,121		)	—			—			—			—			(5,121		)
Accumulated other comprehensive income (loss), net of tax	(23,817		)	(23,817		)	(23,817		)	(23,817		)	71,451			(23,817		)
Retained earnings (accumulated deficit)	253,578			244,559			208,502			15,114			(468,175		)	253,578
Total Stockholders' Equity	662,724			1,501,690			1,316,263			65,328			(2,883,281		)	662,724
Total Liabilities and Stockholders' Equity	$	2,814,213		$	4,097,453		$	2,958,263		$	143,177		$	(7,376,604	)	$	2,636,502

Condensed Consolidating Balance Sheet

March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318
Accounts receivable, net	—			14,539			66,523			6,796			—			87,858
Inventories	—			8,667			60,297			6,182			(1,146		)	74,000
Deferred income tax assets	452			674			6,497			474			—			8,097
Prepaid expenses and other current assets	5,731			141			3,804			758			—			10,434
Total current assets	17,570			24,021			137,121			24,141			(1,146		)	201,707

Property and equipment, net	10,726			175			2,207			636			—			13,744
Goodwill	—			66,007			204,205			20,439			—			290,651
Intangible assets, net	—			192,325			1,854,798			87,577			—			2,134,700
Other long-term assets	—			1,165			—			—			—			1,165
Intercompany receivables	1,210,017			2,607,054			668,169			8,764			(4,494,004		)	—
Investment in subsidiary	1,545,575			1,228,535			65,564			—			(2,839,674		)	—
Total Assets	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,959		$	6,829		$	32,898		$	4,429		$	—		$	46,115
Accrued interest payable	—			11,974			—			—			—			11,974
Other accrued liabilities	10,378			1,153			25,795			3,622			—			40,948
Total current liabilities	12,337			19,956			58,693			8,051			—			99,037

Long-term debt
Principal amount	—			1,593,600			—			—			—			1,593,600
Less unamortized debt costs	—			(32,327		)	—			—			—			(32,327		)
Long-term debt, net	—			1,561,273			—			—			—			1,561,273

Deferred income tax liabilities	—			59,038			292,504			27			—			351,569
Other long-term liabilities	—			—			2,293			171			—			2,464
Intercompany payables	2,143,927			1,001,219			1,279,833			69,025			(4,494,004		)	—
Total Liabilities	2,156,264			2,641,486			1,633,323			77,274			(4,494,004		)	2,014,343

Stockholders' Equity
Common stock	525			—			—			—			—			525
Additional paid-in capital	426,584			1,280,948			1,131,578			74,031			(2,486,557		)	426,584
Treasury stock, at cost	(3,478		)	—			—			—			—			(3,478		)
Accumulated other comprehensive income (loss), net of tax	(23,412		)	(23,412		)	(23,412		)	(23,412		)	70,236			(23,412		)
Retained earnings (accumulated deficit)	227,405			220,260			190,575			13,664			(424,499		)	227,405
Total Stockholders' Equity	627,624			1,477,796			1,298,741			64,283			(2,840,820		)	627,624
Total Liabilities and Stockholders' Equity	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Condensed Consolidating Statement of Cash Flows

Three Months Ended June 30, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	26,173		$	24,299		$	17,927		$	1,450		$	(43,676	)	$	26,173
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	989			146			4,445			140			—			5,720
Gain on sale of asset	—			—			—			(36		)	—			(36		)
Deferred income taxes	141			395			10,866			134			—			11,536
Amortization of debt origination costs	—			2,138			—			—			—			2,138
Stock-based compensation costs	3,047			—			—			—			—			3,047
Loss on extinguishment of debt	—			451			—			—			—			451
Equity in income of subsidiaries	(25,306		)	(16,955		)	(1,450		)	—			43,711			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			3,171			735			(1,328		)	—			2,578
Inventories	—			1,175			(1,457		)	106			(35		)	(211		)
Prepaid expenses and other current assets	(2,152		)	(102		)	722			10			—			(1,522		)
Accounts payable	861			(325		)	880			(633		)	—			783
Accrued liabilities	(5,668		)	(2,368		)	975			(75		)	—			(7,136		)
Net cash provided by (used in) operating activities	(1,915		)	12,025			33,643			(232		)	—			43,521

Investing Activities
Purchases of property and equipment	(648		)	—			(27		)	(105		)	—			(780		)
Proceeds from the sale of property and equipment	—			—			—			344			—			344
Net cash (used in) provided by investing activities	(648		)	—			(27		)	239			—			(436		)

Financing Activities
Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
Borrowings under revolving credit agreement	—			15,000			—			—			—			15,000
Repayments under revolving credit agreement	—			(35,000		)	—			—			—			(35,000		)
Payments of debt origination costs	—			(4,172		)	—			—			—			(4,172		)
Proceeds from exercise of stock options	6,328			—			—			—			—			6,328
Proceeds from restricted stock exercises	544			—			—			—			—			544
Excess tax benefits from share-based awards	1,600			—			—			—			—			1,600
Fair value of shares surrendered as payment of tax withholding	(2,187		)	—			—			—			—			(2,187		)
Intercompany activity, net	(4,277		)	37,147			(33,616		)	746			—			—
Net cash provided by (used in) financing activities	2,008			(12,025		)	(33,616		)	746			—			(42,887		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			82			—			82
(Decrease) increase in cash and cash equivalents	(555		)	—			—			835			—			280
Cash and cash equivalents - beginning of period	11,387			—			—			9,931			—			21,318
Cash and cash equivalents - end of period	$	10,832		$	—		$	—		$	10,766		$	—		$	21,598

Condensed Consolidating Statement of Cash Flows

Three Months Ended June 30, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	16,732		$	17,506		$	10,109		$	(959	)	$	(26,656	)	$	16,732
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	642			145			2,089			85			—			2,961
Deferred income taxes	(1		)	892			6,330			(81		)	—			7,140
Amortization of debt origination costs	—			995			—			—			—			995
Stock-based compensation costs	1,858			—			—			—			—			1,858
Equity in income of subsidiaries	(15,679		)	(10,898		)	959			—			25,618			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	467			(130		)	8,941			(2,322		)	—			6,956
Inventories	—			3,288			(2,822		)	36			1,038			1,540
Prepaid expenses and other current assets	947			(920		)	(1,706		)	(524		)	—			(2,203		)
Accounts payable	(936		)	(916		)	(2,918		)	1,674			—			(3,096		)
Accrued liabilities	(4,800		)	4,733			(5,663		)	2,518			—			(3,212		)
Net cash provided by (used in) operating activities	(770		)	14,695			15,319			427			—			29,671

Investing Activities
Purchases of property and equipment	(385		)	—			(11		)	(100		)	—			(496		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(77,991		)	—			77,991			—			—
Net cash used in investing activities	(385		)	(77,991		)	(11		)	(100		)	—			(78,487		)

Financing Activities
Borrowings under revolving credit agreement	—			65,000			—			—			—			65,000
Repayments under revolving credit agreement	—			(30,000		)	—			—			—			(30,000		)
Payment of debt origination costs	—			(74		)	—			—			—			(74		)
Proceeds from exercise of stock options	1,294			—			—			—			—			1,294
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	950			—			—			—			—			950
Fair value of shares surrendered as payment of tax withholding	(1,171		)	—			—			—			—			(1,171		)
Intercompany activity, net	(13,700		)	28,370			(15,308		)	638			—			—
Net cash provided by (used in) financing activities	(12,570		)	63,296			(15,308		)	638			—			36,056

Effect of exchange rate changes on cash and cash equivalents	—			—			—			104			—			104
(Decrease) increase in cash and cash equivalents	(13,725		)	—			—			1,069			—			(12,656		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	10,919		$	—		$	—		$	4,756		$	—		$	15,675

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%
Term of original maturities, cash equivalents, up to and including	3 months
Shipping, warehousing and handling costs	$ 8.7	$ 7.7

Acquisitions (Narrative) (Details) (USD $)	3 Months Ended		0 Months Ended	3 Months Ended
Acquisitions (Narrative) (Details) (USD $)	Jun. 30, 2015	Mar. 31, 2015	Sep. 03, 2014 Insight Pharmaceuticals brand	Jun. 30, 2015 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals Intangible assets	Sep. 03, 2014 Insight Pharmaceuticals Inventory	Sep. 03, 2014 Insight Pharmaceuticals Property, plant and equipment	Apr. 30, 2014 Hydralyte
Business Acquisition [Line Items]
Purchase price of acquisition			$ 753,200,000
Number of pharmaceutical brands acquired as a result of acquisition			27
Number of brands sold			1
Non-amortizable intangible assets					599,600,000
Amortizable intangible assets					124,800,000
Purchased amortizable intangible assets, weighted average useful life				16 years 2 months 12 days
Purchased amortizable intangible assets, weighted average remaining period	14 years 5 months			15 years 4 months 1 day
Goodwill	290,867,000	290,651,000			103,560,000				1,224,000
Value of assets sold on acquisition date, excluded from purchase price					18,500,000	17,700,000	600,000	200,000
Non-amortizable intangible assets					$ 724,374,000				$ 73,580,000

Acquisitions (Allocation of Assets Acquired and Liabilities Assumed) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte
Purchase Price
Cash acquired			$ 3,507
Accounts receivable			26,012
Inventories			23,456	1,970
Deferred income tax assets - current			1,032
Prepaids and other current assets			1,341
Property, plant and equipment			2,308	1,267
Goodwill	290,867	290,651	103,560	1,224
Intangible assets			724,374	73,580
Total assets acquired			885,590	78,041
Accounts payable			16,079
Accrued expenses			8,539	38
Deferred income tax liabilities - long term			107,799
Other long term liabilities				12
Total liabilities assumed			132,417	50
Net assets acquired			$ 753,173	$ 77,991

Accounts Receivable (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 95,020	$ 97,764
Less allowances for discounts, returns and uncollectible accounts	(9,444)	(9,906)
Accounts receivable, net	85,576	87,858
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	93,064	95,411
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,956	$ 2,353

Inventories (Details) (USD $)	Jun. 30, 2015	Mar. 31, 2015
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 7,748,000	$ 7,588,000
Finished goods	66,329,000	66,412,000
Inventories	74,077,000	74,000,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 3,800,000	$ 4,100,000

Property and Equipment (Details) (USD $)	3 Months Ended
Property and Equipment (Details) (USD $)	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Components of Property and Equipment
Property and equipment, gross	$ 26,119,000		$ 25,700,000
Accumulated depreciation	(12,965,000)		(11,956,000)
Property and equipment, net	13,154,000		13,744,000
Depreciation	1,300,000	700,000
Machinery
Components of Property and Equipment
Property and equipment, gross	3,943,000		4,743,000
Computer equipment
Components of Property and Equipment
Property and equipment, gross	12,509,000		11,339,000
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,371,000		2,484,000
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,296,000		$ 7,134,000

Goodwill (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended				3 Months Ended
	Jun. 30, 2015	Jun. 30, 2015 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte	Jun. 30, 2015 North American OTC Healthcare	Jun. 30, 2015 International OTC Healthcare	Jun. 30, 2015 Household Cleaning
Goodwill [Roll Forward]
Balance — March 31, 2015	$ 290,651		$ 103,560	$ 1,224	$ 263,411	$ 20,440	$ 6,800
Adjustments	305	300			305	0	0
Effects of foreign currency exchange rates	(89)				0	(89)	0
Balance — June 30, 2015	$ 290,867		$ 103,560	$ 1,224	$ 263,716	$ 20,351	$ 6,800

Goodwill (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended	3 Months Ended
	Jun. 30, 2015 business	Mar. 31, 2015 business	Jun. 30, 2015 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte
Goodwill [Line Items]
Number of acquisitions	2	2
Goodwill	$ 290,867	$ 290,651		$ 103,560	$ 1,224
Goodwill adjustments	$ 305		$ 300

Intangible Assets (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$ 1,873,029
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, additions	4,460
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates	(1)
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance	2,231,470
Totals, effects of foreign currency exchange rate	(381)
Totals, gross, ending balance	2,231,089
Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, beginning balance	96,770
Totals, accumulated amortization, additions	4,460
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates	(1)
Totals, accumulated amortization, ending balance	101,229
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	256,831
Intangible Assets, Net [Abstract]
Intangible assets, net	2,129,860	2,134,700
North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	1,676,991
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	231,251
Intangible Assets, Net [Abstract]
Intangible assets, net	1,908,242
International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	85,766
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,594
Intangible Assets, Net [Abstract]
Intangible assets, net	87,360
Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	110,272
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	23,986
Intangible Assets, Net [Abstract]
Intangible assets, net	134,258
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks, beginning balance	358,066
Finite Lived Trademarks, effects of foreign currency exchange rate	(6)
Finite Lived Trademarks, ending balance	358,060
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks, accumulated amortization, beginning balance	96,770
Totals, accumulated amortization, additions	4,460
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates	(1)
Finite Lived Trademarks, accumulated amortization, ending balance	101,229
Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, additions	4,460
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates	(1)
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	256,831
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance	1,873,404
Indefinite Lived Trademarks, effects of foreign currency exchange rate	(375)
Indefinite Lived Trademarks, ending balance	$ 1,873,029

Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended		0 Months Ended	3 Months Ended
Intangible Assets (Narrative) (Details) (USD $)	Jun. 30, 2015 business	Mar. 31, 2015 business	Jun. 30, 2015 Minimum	Jun. 30, 2015 Maximum	Sep. 03, 2014 Insight Pharmaceuticals	Jun. 30, 2015 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte
Finite-Lived Intangible Assets [Line Items]
Number of acquisitions	2	2
Intangible assets							$ 724,374,000	$ 73,580,000
Acquired intangible assets sold on acquisition date					17,700,000
Weighted average remaining life for finite-lived intangible assets	14 years 5 months					15 years 4 months 1 day
Amortization expense	$ 4,460,000
Intangible assets, useful lives			10 years	30 years

Intangible Assets (Expected Amortization Expense) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2016 (Remaining nine months ending March 31, 2016)	$ 13,401
2016	17,868
2017	17,868
2018	17,868
2019	17,868
Thereafter	171,958
Intangible assets, net	$ 256,831

Other Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued marketing costs	$ 20,817	$ 16,903
Accrued compensation costs	3,405	8,840
Accrued broker commissions	741	1,134
Income taxes payable	2,187	2,642
Accrued professional fees	1,958	2,769
Deferred rent	985	1,021
Accrued production costs	4,137	5,610
Accrued lease termination costs	767	669
Other accrued liabilities	1,741	1,360
Total other accrued liabilities	$ 36,738	$ 40,948

Long-Term Debt (2012 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012	Jan. 31, 2012 2012 Senior Notes	Jun. 30, 2015 Senior Notes 2012 Senior Notes	Mar. 31, 2015 Senior Notes 2012 Senior Notes	Jan. 31, 2012 Senior Notes 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount						$ 250,000,000.0
Debt instrument, stated interest rate (percent)				8.125%	8.125%	8.125%
Percentage of subsidiary owned	100.00%	100.00%
Debt issuance costs capitalized			$ 12,600,000

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) (USD $)	3 Months Ended				0 Months Ended	3 Months Ended													0 Months Ended	3 Months Ended			0 Months Ended				3 Months Ended	0 Months Ended				0 Months Ended			0 Months Ended					0 Months Ended			0 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 17, 2013	Jan. 31, 2012	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility	Jun. 30, 2014 2012 ABL Revolver Revolving Credit Facility	Jun. 30, 2015 2012 ABL Revolver Revolving Credit Facility	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility LIBOR	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility LIBOR Minimum	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility LIBOR Maximum	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility Base Rate	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility Base Rate Minimum	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility Base Rate Maximum	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility Base Rate Federal Funds Rate	Jan. 31, 2012 2012 ABL Revolver Revolving Credit Facility Base Rate LIBOR	Jan. 31, 2012 Term Loan and ABL Revolver 2012	Sep. 03, 2014 2012 ABL Revolver Amendment 3 Revolving Credit Facility	Jan. 31, 2012 Term Loans 2012 Term Loan	Jun. 30, 2015 Term Loans 2012 Term Loan	Sep. 03, 2014 Term Loans 2012 Term Loan	Jan. 31, 2012 Term Loans 2012 Term Loan	Jan. 31, 2012 Term Loans 2012 Term Loan LIBOR Minimum	Jan. 31, 2012 Term Loans 2012 Term Loan Base Rate	Jan. 31, 2012 Term Loans 2012 Term Loan Base Rate Federal Funds Rate	Jan. 31, 2012 Term Loans 2012 Term Loan Base Rate LIBOR	Mar. 31, 2013 Term Loans Amendment 1, 2012 Term Loan	Feb. 21, 2013 Term Loans Amendment 1, 2012 Term Loan LIBOR	Feb. 21, 2013 Term Loans Amendment 1, 2012 Term Loan LIBOR	Feb. 21, 2013 Term Loans Amendment 1, 2012 Term Loan Base Rate	Sep. 03, 2014 Term Loans Amendment 2, 2012 Term Loan	Sep. 03, 2014 Term Loans Amendment 2, 2012 Term Loan LIBOR	Sep. 03, 2014 Term Loans Amendment 2, 2012 Term Loan Base Rate	Sep. 03, 2014 Term B-2 Amendment 2, 2012 Term Loan	Sep. 03, 2014 Term B-2 Amendment 2, 2012 Term Loan LIBOR	Sep. 03, 2014 Term B-2 Amendment 2, 2012 Term Loan LIBOR	Sep. 03, 2014 Term B-2 Amendment 2, 2012 Term Loan Base Rate	May 08, 2015 Term B-2 Amendment 3, 2012 Term Loan	May 08, 2015 Loans Payable, Term B-3 Amendment 3, 2012 Term Loan	May 08, 2015 Loans Payable, Term B-3 Amendment 3, 2012 Term Loan LIBOR	May 08, 2015 Loans Payable, Term B-3 Amendment 3, 2012 Term Loan Base Rate	May 08, 2015 Loans Payable, Term B-1 Amendment 3, 2012 Term Loan	Jun. 09, 2015 2012 ABL Revolver Amendment 4, 2012 ABL Revolver Revolving Credit Facility	Jun. 09, 2015 2012 ABL Revolver Amendment 4, 2012 ABL Revolver Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, face amount																						$ 660,000,000.0												$ 720,000,000.0				$ 645,000,000.0	$ 852,500,000.0			$ 207,500,000.0
Debt instrument, maturity term					5 years														7 years																								5 years
Line of credit facility, maximum borrowing capacity							135,000,000	50,000,000.0
Line of credit facility, increase in borrowing capacity							85,000,000											40,000,000																										35,000,000.0
Debt instrument, interest rate, increase/(decrease) (percent)						(0.25%)
Debt instrument, discount, percentage																						1.50%
Proceeds from issuance of long-term debt																			650,100,000
Debt issuance costs capitalized																	20,600,000
Percentage of subsidiary owned			100.00%	100.00%
Debt instrument, basis spread on variable rate (percent)																							1.00%					2.75%				3.125%			3.50%					2.75%
Debt instrument, stated interest rate, minimum (percent)																																								0.75%	1.75%
Debt instrument, reference rate floor (percent)																													1.00%	2.00%	1.00%		2.00%			1.00%	2.00%
Loss on extinguishment of debt	$ 451,000	$ 0																									$ 1,400,000
Debt instrument, step down interest rate (percent)																																			3.25%
Debt instrument, quarterly payment, percent of original principal amount (percent)																					0.25%																		0.25%
Debt instrument, basis spread on variable rate, fixed component (percent)															0.50%	1.00%								2.00%	0.50%	1.00%
Debt instrument, average interest rate during period (percent)																				4.80%
Debt instrument, variable rate (percent)									1.75%			0.75%
Debt instrument, conditional variable rate (percent)										2.00%	2.25%		1.00%	1.25%
Line of credit facility, commitment fee percentage					0.50%
Line of credit facility, conditional commitment fee percentage					0.375%
Line of credit facility, interest rate at period end (percent)							2.30%

Long-Term Debt (2013 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012	Jun. 30, 2015 Senior Notes 2013 Senior Notes	Mar. 31, 2015 Senior Notes 2013 Senior Notes	Dec. 17, 2013 Senior Notes 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount					$ 400,000,000.0
Debt instrument, stated interest rate (percent)			5.375%	5.375%	5.375%
Percentage of subsidiary owned	100.00%	100.00%
Debt issuance costs capitalized					$ 7,200,000

Long-Term Debt (Redemptions and Restrictions) (Details) (USD $)	3 Months Ended				3 Months Ended		0 Months Ended			0 Months Ended	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Mar. 31, 2015 Adjustments for new accounting pronouncement	Jun. 30, 2015 2012 ABL Revolver Revolving Credit Facility	Jun. 30, 2015 Senior Notes 2012 Senior Notes	Jan. 31, 2012 Senior Notes 2012 Senior Notes Prior to February 1, 2016	Jan. 31, 2012 Senior Notes 2012 Senior Notes Prior to February 1, 2015	Jan. 31, 2012 Senior Notes 2012 Senior Notes Prior to February 1, 2015	Jan. 31, 2012 Senior Notes 2012 Senior Notes Upon Change in Control	Jun. 30, 2015 Senior Notes 2013 Senior Notes	Jun. 30, 2015 Senior Notes 2013 Senior Notes Prior to December 15, 2016	Jun. 30, 2015 Senior Notes 2013 Senior Notes On Or After December 15, 2016	Jun. 30, 2015 Term Loans 2012 Term Loan
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage							100.00%	108.125%		101.00%	101.00%	100.00%	105.375%
Debt instrument, percentage of principal amount eligible for redemption									35.00%			35.00%
Other long-term assets	$ (1,562,000)		$ (1,165,000)	$ 27,400,000
Debt instrument, unamortized discount	33,534,000		32,327,000
Unamortized debt issuance expense and discount						8,300,000					6,000,000			19,200,000
Repayments of long-term debt	25,000,000	0			46,100,000
Remaining borrowing capacity					$ 63,000,000

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015 2012 ABL Revolver Revolving Credit Facility	Mar. 31, 2015 2012 ABL Revolver Revolving Credit Facility	Jun. 30, 2015 Senior Notes 2013 Senior Notes	Mar. 31, 2015 Senior Notes 2013 Senior Notes	Dec. 17, 2013 Senior Notes 2013 Senior Notes	Jun. 30, 2015 Senior Notes 2012 Senior Notes	Mar. 31, 2015 Senior Notes 2012 Senior Notes	Jan. 31, 2012 Senior Notes 2012 Senior Notes	Jun. 30, 2015 Loans Payable, Term B-3 2012 Senior Notes	Mar. 31, 2015 Loans Payable, Term B-3 2012 Senior Notes	Jun. 30, 2015 Loans Payable, Term B-3 2012 Senior Notes Base Rate	Mar. 31, 2015 Loans Payable, Term B-3 2012 Senior Notes Base Rate	Jun. 30, 2015 Loans Payable, Term B-3 2012 Senior Notes LIBOR	Mar. 31, 2015 Loans Payable, Term B-3 2012 Senior Notes LIBOR
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)					5.375%	5.375%	5.375%	8.125%	8.125%	8.125%
Debt instrument, reference rate floor (percent)													1.75%	1.75%	0.75%	0.75%
Long-term debt, gross	$ 1,548,600	$ 1,593,600	$ 46,100	$ 66,100	$ 400,000	$ 400,000		$ 250,000	$ 250,000		$ 852,500	$ 877,500
Current portion of long-term debt	8,525	0
Principal amount	1,540,075	1,593,600
Less: unamortized debt costs	(33,534)	(32,327)
Long-term debt, net	$ 1,506,541	$ 1,561,273

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Debt Disclosure [Abstract]
2016 (remaining nine months ending March 31, 2016)	$ 6,394
2017	8,525
2018	8,525
2019	8,525
2020	258,525
Thereafter	1,258,106
Long-term debt, gross	$ 1,548,600	$ 1,593,600

Fair Value Measurements (Details) (USD $) In Millions, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
2012 ABL Revolver \| Market Value \| Fair Value, Inputs, Level 2 \| Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 45.9	$ 65.7
2012 ABL Revolver \| Carrying Value \| Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	46.1	66.1
Senior Notes \| 2013 Senior Notes \| Market Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	398.5	405.0
Senior Notes \| 2013 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400.0	400.0
Senior Notes \| 2012 Senior Notes \| Market Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	266.9	268.1
Senior Notes \| 2012 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250.0	250.0
Term Loans \| 2012 Term Loan \| Market Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	851.4	880.5
Term Loans \| 2012 Term Loan \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 852.5	$ 877.5

Stockholders' Equity (Details) (USD $)			3 Months Ended
Stockholders' Equity (Details) (USD $)	Jun. 30, 2015 vote	Mar. 31, 2015	Jun. 30, 2015 Restricted Shares	Jun. 30, 2014 Restricted Shares
Class of Stock [Line Items]
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned	1
Restricted stock repurchased during period, shares			39,429	33,740
Restricted stock acquired, average cost per share (in USD per share)			$ 41.66	$ 33.03

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Accumulated Other Comprehensive Income [Abstract]
Cumulative translation adjustment	$ (23,817)	$ (23,412)
Accumulated other comprehensive loss, net of tax	$ (23,817)	$ (23,412)

(Earnings Per Share) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Numerator
Net income	$ 26,173	$ 16,732
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,548	51,956
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	410	577
Denominator for diluted earnings per share (in shares)	52,958	52,533
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.50	$ 0.32
Diluted net earnings per share (in USD per share)	$ 0.49	$ 0.32

Share-Based Compensation (Narrative) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		0 Months Ended			3 Months Ended		0 Months Ended			3 Months Ended								0 Months Ended	1 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 01, 2015 President and CEO	Apr. 22, 2015 President and CEO	May 11, 2015 Restricted Stock Units (RSUs)	Jun. 30, 2015 Restricted Stock Units (RSUs)	Jun. 30, 2014 Restricted Stock Units (RSUs)	May 11, 2015 Restricted Stock Units (RSUs) Share-based compensation award, tranche 1	May 11, 2015 Restricted Stock Units (RSUs) Share-based compensation award, tranche 2	May 11, 2015 Stock Options	Jun. 30, 2015 Stock Options Minimum	Jun. 30, 2015 Stock Options Maximum	Jun. 30, 2015 Restricted Shares	Jun. 30, 2014 Restricted Shares	Jun. 30, 2015 Restricted Shares Employee	Jun. 30, 2015 Restricted Shares Director	Jun. 30, 2015 Restricted Shares Minimum	Jun. 30, 2015 Restricted Shares Maximum	May 31, 2014 2005 Long-Term Incentive Plan	Jun. 30, 2014 2005 Long-Term Incentive Plan
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan	5,000,000
Number of additional shares authorized																				1,800,000
Maximum number of shares per participant, 12 month period																			1,000,000	2,500,000
Extension of plan term																				10 years
Share-based compensation costs charged against income	$ 3.0	$ 1.9
Tax benefit recognized from share-based compensation expense	1.1	0.7
Accelerated share-based compensation expense			0.8
Granted in period (in shares)				57,924	185,904	243,800	96,600	163,404	22,500
Stock options granted (in shares)	186,300	307,500								186,302
Award vesting period								3 years	3 years	3 years	3 years	5 years			3 years	1 year	3 years	5 years
Annual award vesting percentage									33.30%	33.30%
Term from grant date, exercisable										10 years
Exercise price of granted awards (in USD per share)	$ 41.44	$ 33.50								$ 41.44
Restricted Shares
Granted, weighted-average grant-date fair value (in USD per share)						$ 41.85	$ 33.50						$ 41.85	$ 33.50
Options, Additional Disclosures:
Award exercisability period, from date of grant												10 years
Options granted, weighted-average grant-date fair value (in USD per share)	$ 16.95	$ 15.93
Options exercised, aggregate intrinsic value	8.1
Unrecognized compensation costs related to nonvested awards	14.5
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition	1 year 3 months 18 days
Total fair value of vested shares	6.2	4.7
Cash received from exercise of stock options	6.3	1.3
Tax benefit realized from exercise of stock options	$ 1.0	$ 1.0
Shares available for issuance under the Plan	2,600,000

Share-Based Compensation (Restricted Stock Units Activity) (Details) (Restricted Stock Units (RSUs), USD $)	0 Months Ended	3 Months Ended
	May 11, 2015	Jun. 30, 2015	Jun. 30, 2014
Restricted Stock Units (RSUs)
Shares
Outstanding, beginning of period (in shares)		362,300	437,500
Granted (in shares)	185,904	243,800	96,600
Vested and issued (in shares)		(138,900)	(93,700)
Forfeited (in shares)		(1,400)	(14,400)
Outstanding, end of period (in shares)		465,800	426,000
Vested, end of period (in shares)		76,600	69,600
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)		$ 22.74	$ 16.76
Granted, weighted-average grant-date fair value (in USD per share)		$ 41.85	$ 33.50
Vested and issued, weighted-average grant-date fair value (in USD per share)		$ 19.35	$ 15.12
Forfeited, weighted-average grant-date fair value (in USD per share)		$ 33.50	$ 20.78
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)		$ 33.72	$ 20.78
Vested, end of period, weighted-average grant-date fair value (in USD per share)		$ 11.62	$ 9.34

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (percent)	40.20%	47.30%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years 0 months
Risk-free rate (percent)	1.70%	2.20%

Share-Based Compensation (Stock Option Activity) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Shares
Outstanding, beginning of period (in shares)	871,200	994,900
Granted (in shares)	186,300	307,500
Exercised (in shares)	(330,400)	(93,800)
Forfeited or expired (in shares)	(900)	(31,600)
Outstanding, end of period (in shares)	726,200	1,177,000
Exercisable, end of period (in shares)	322,500	375,100
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 23.40	$ 15.24
Granted, weighted-average exercise price (in USD per share)	$ 41.44	$ 33.50
Exercised, weighted-average exercise price (in USD per share)	$ 19.15	$ 13.80
Forfeited or expired, weighted-average exercise price (in USD per share)	$ 33.50	$ 25.49
Outstanding, end of period, weighted-average exercise price (in USD per share)	$ 29.95	$ 19.85
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 21.54	$ 15.23
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	8 years 3 months 18 days	7 years 9 months 18 days
Exercisable, end of period, weighted-average remaining contractual term	7 years 2 months 12 days	7 years 3 months 18 days
Outstanding, end of period, aggregate intrinsic value	$ 11,830	$ 16,527
Exercisable, end of period, aggregate intrinsic value	$ 7,966	$ 6,998

Income Taxes (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	34.80%	40.60%
Net operating loss carryforwards	$ 53.0
Operating loss carryforwards, limitation on use, annual amount	33.6
Uncertain tax liability	$ 3.4		$ 3.4

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Operating Leased Assets [Line Items]
2016 (Remaining nine months ending March 31, 2016)	$ 1,540,000
2017	1,938,000
2018	1,871,000
2019	1,864,000
2020	1,695,000
Thereafter	770,000
Total future minimum payments due	9,678,000		9,957,000
Future minimum sublease rentals	1,300,000
Less: Sublease rentals	(1,342,000)		(1,401,000)
Minimum lease payments, less minimum sublease rentals	8,336,000		8,556,000
Rent expense	400,000	400,000
Facilities
Operating Leased Assets [Line Items]
2016 (Remaining nine months ending March 31, 2016)	1,312,000
2017	1,861,000
2018	1,871,000
2019	1,864,000
2020	1,695,000
Thereafter	770,000
Total future minimum payments due	9,373,000
Equipment
Operating Leased Assets [Line Items]
2016 (Remaining nine months ending March 31, 2016)	228,000
2017	77,000
2018	0
2019	0
2020	0
Thereafter	0
Total future minimum payments due	$ 305,000

Commitments and Contingencies (Long-term Supply Agreement) (Details) (Third-party Manufacturing, USD $) In Thousands, unless otherwise specified	0 Months Ended
	Nov. 01, 2009	Jun. 30, 2015
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2016 (Remaining nine months ending March 31, 2016)		$ 803
2017		1,044
2018		1,013
2019		982
2020		560
Thereafter		0
Total purchase commitment		$ 4,402

Concentrations of Risk (Details)	3 Months Ended
Concentrations of Risk (Details)	Jun. 30, 2015 brand	Jun. 30, 2014 brand
Concentration Risk [Line Items]
Number of third-party manufacturers	98	61
Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	43.90%	42.00%
Number of highest selling brands comprising group against which concentration risk is measured	5	5
Sales \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	19.90%	19.20%
Number of customers exceeding concentration risk benchmark	1
Sales \| Customer Concentration Risk \| Customer No. 2
Concentration Risk [Line Items]
Concentration risk, percentage	9.40%
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	83.90%	84.50%
Number of third-party manufacturers with long-term contracts	47	27
Accounts Receivable \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	21.80%

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information, Profit (Loss):
Net sales	$ 191,287	$ 144,541
Other revenues	845	1,161
Total revenues	192,132	145,702
Cost of sales	79,896	63,836
Gross profit	112,236	81,866
Advertising and promotion	26,422	19,096
Contribution margin	85,814	62,770
Other operating expenses	23,309	19,967
Operating income	62,505	42,803
Other expense	22,335	14,653
Income before income taxes	40,170	28,150
Provision for income taxes	13,997	11,418
Net income	26,173	16,732
Geographic Concentration Risk \| Sales \| United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	87.30%	84.50%
Geographic Concentration Risk \| Sales \| Canada
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	5.10%	5.60%
Geographic Concentration Risk \| Sales \| Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	5.70%	5.20%
Geographic Concentration Risk \| Goodwill and Intangible Assets \| United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	95.60%
Geographic Concentration Risk \| Goodwill and Intangible Assets \| Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	4.40%
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	155,611	110,256
Other revenues	40	177
Total revenues	155,651	110,433
Cost of sales	58,126	42,340
Gross profit	97,525	68,093
Advertising and promotion	23,195	16,353
Contribution margin	74,330	51,740
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	14,209	13,692
Other revenues	0	35
Total revenues	14,209	13,727
Cost of sales	5,290	5,078
Gross profit	8,919	8,649
Advertising and promotion	2,723	2,339
Contribution margin	6,196	6,310
Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	21,467	20,593
Other revenues	805	949
Total revenues	22,272	21,542
Cost of sales	16,480	16,418
Gross profit	5,792	5,124
Advertising and promotion	504	404
Contribution margin	5,288	4,720
Operating Segments
Segment Reporting Information, Profit (Loss):
Net sales	192,015	145,258
Operating Segments \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	156,339	110,973
Operating Segments \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	14,209	13,692
Operating Segments \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	21,467	20,593
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Net sales	(728)	(717)
Intersegment Eliminations \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	(728)	(717)
Intersegment Eliminations \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	0	0
Intersegment Eliminations \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	$ 0	$ 0

Business Segments (Revenue by Product) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Revenue from External Customer [Line Items]
Revenues	$ 192,132	$ 145,702
Analgesics
Revenue from External Customer [Line Items]
Revenues	27,378	25,696
Cough & Cold
Revenue from External Customer [Line Items]
Revenues	24,265	24,841
Women's Health
Revenue from External Customer [Line Items]
Revenues	33,608	886
Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	24,128	23,135
Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	28,262	25,367
Dermatologicals
Revenue from External Customer [Line Items]
Revenues	20,629	12,802
Oral Care
Revenue from External Customer [Line Items]
Revenues	10,171	10,249
Other OTC
Revenue from External Customer [Line Items]
Revenues	1,419	1,184
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	22,272	21,542
North American OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	155,651	110,433
North American OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Revenues	26,848	25,031
North American OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Revenues	19,759	20,043
North American OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Revenues	32,908	368
North American OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	20,320	20,638
North American OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	24,332	20,725
North American OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Revenues	20,095	12,260
North American OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Revenues	9,977	10,187
North American OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Revenues	1,412	1,181
International OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	14,209	13,727
International OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Revenues	530	665
International OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Revenues	4,506	4,798
International OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Revenues	700	518
International OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	3,808	2,497
International OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	3,930	4,642
International OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Revenues	534	542
International OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Revenues	194	62
International OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Revenues	7	3
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	22,272	21,542
Household Cleaning \| Analgesics
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Cough & Cold
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Women's Health
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Dermatologicals
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Oral Care
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Other OTC
Revenue from External Customer [Line Items]
Revenues	0	0
Household Cleaning \| Household Cleaning
Revenue from External Customer [Line Items]
Revenues	$ 22,272	$ 21,542

Business Segments (Assets by Segment) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 290,867	$ 290,651
Indefinite-lived intangibles	1,873,029
Finite-lived intangibles	256,831
Intangible assets, net	2,129,860	2,134,700
Intangible assets, net (including goodwill)	2,420,727
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	263,716	263,411
Indefinite-lived intangibles	1,676,991
Finite-lived intangibles	231,251
Intangible assets, net	1,908,242
Intangible assets, net (including goodwill)	2,171,958
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	20,351	20,440
Indefinite-lived intangibles	85,766
Finite-lived intangibles	1,594
Intangible assets, net	87,360
Intangible assets, net (including goodwill)	107,711
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,800	6,800
Indefinite-lived intangibles	110,272
Finite-lived intangibles	23,986
Intangible assets, net	134,258
Intangible assets, net (including goodwill)	$ 141,058

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Revenues
Net sales	$ 191,287	$ 144,541
Other revenues	845	1,161
Total revenues	192,132	145,702
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	79,896	63,836
Gross profit	112,236	81,866
Operating Expenses
Advertising and promotion	26,422	19,096
General and administrative	17,589	17,006
Depreciation and amortization	5,720	2,961
Total operating expenses	49,731	39,063
Operating income	62,505	42,803
Other (income) expense
Interest income	(27)	(32)
Interest expense	21,911	14,685
Loss on extinguishment of debt	451	0
Equity in (income) loss of subsidiaries	0	0
Total other expense	22,335	14,653
Income before income taxes	40,170	28,150
Provision for income taxes	13,997	11,418
Net income	26,173	16,732
Comprehensive income, net of tax:
Currency translation adjustments	(405)	2,726
Total other comprehensive income (loss)	(405)	2,726
Comprehensive income	25,768	19,458
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0
Other revenues	0	0
Total revenues	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0
Gross profit	0	0
Operating Expenses
Advertising and promotion	0	0
General and administrative	1,315	1,145
Depreciation and amortization	989	642
Total operating expenses	2,304	1,787
Operating income	(2,304)	(1,787)
Other (income) expense
Interest income	(12,049)	(12,133)
Interest expense	8,490	8,548
Loss on extinguishment of debt	0
Equity in (income) loss of subsidiaries	(25,306)	(15,679)
Total other expense	(28,865)	(19,264)
Income before income taxes	26,561	17,477
Provision for income taxes	388	745
Net income	26,173	16,732
Comprehensive income, net of tax:
Currency translation adjustments	(405)	2,726
Total other comprehensive income (loss)	(405)	2,726
Comprehensive income	25,768	19,458
Prestige Brands, Inc., the issuer or the borrower
Revenues
Net sales	27,883	25,410
Other revenues	96	130
Total revenues	27,979	25,540
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	10,441	9,448
Gross profit	17,538	16,092
Operating Expenses
Advertising and promotion	2,517	2,689
General and administrative	2,555	2,473
Depreciation and amortization	146	145
Total operating expenses	5,218	5,307
Operating income	12,320	10,785
Other (income) expense
Interest income	(21,408)	(14,225)
Interest expense	21,908	14,685
Loss on extinguishment of debt	451
Equity in (income) loss of subsidiaries	(16,955)	(10,898)
Total other expense	(16,004)	(10,438)
Income before income taxes	28,324	21,223
Provision for income taxes	4,025	3,717
Net income	24,299	17,506
Comprehensive income, net of tax:
Currency translation adjustments	(405)	2,726
Total other comprehensive income (loss)	(405)	2,726
Comprehensive income	23,894	20,232
Combined Subsidiary Guarantors
Revenues
Net sales	152,524	108,898
Other revenues	819	1,099
Total revenues	153,343	109,997
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	66,378	50,515
Gross profit	86,965	59,482
Operating Expenses
Advertising and promotion	21,228	14,066
General and administrative	11,951	8,990
Depreciation and amortization	4,445	2,089
Total operating expenses	37,624	25,145
Operating income	49,341	34,337
Other (income) expense
Interest income	(1,220)	(762)
Interest expense	25,055	17,805
Loss on extinguishment of debt	0
Equity in (income) loss of subsidiaries	(1,450)	959
Total other expense	22,385	18,002
Income before income taxes	26,956	16,335
Provision for income taxes	9,029	6,226
Net income	17,927	10,109
Comprehensive income, net of tax:
Currency translation adjustments	(405)	2,726
Total other comprehensive income (loss)	(405)	2,726
Comprehensive income	17,522	12,835
Combined Non-Guarantor Subsidiaries
Revenues
Net sales	11,608	10,951
Other revenues	498	402
Total revenues	12,106	11,353
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	4,408	4,023
Gross profit	7,698	7,330
Operating Expenses
Advertising and promotion	2,677	2,341
General and administrative	1,768	4,398
Depreciation and amortization	140	85
Total operating expenses	4,585	6,824
Operating income	3,113	506
Other (income) expense
Interest income	(112)	(29)
Interest expense	1,220	764
Loss on extinguishment of debt	0
Equity in (income) loss of subsidiaries	0	0
Total other expense	1,108	735
Income before income taxes	2,005	(229)
Provision for income taxes	555	730
Net income	1,450	(959)
Comprehensive income, net of tax:
Currency translation adjustments	(405)	2,726
Total other comprehensive income (loss)	(405)	2,726
Comprehensive income	1,045	1,767
Eliminations
Revenues
Net sales	(728)	(718)
Other revenues	(568)	(470)
Total revenues	(1,296)	(1,188)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(1,331)	(150)
Gross profit	35	(1,038)
Operating Expenses
Advertising and promotion	0	0
General and administrative	0	0
Depreciation and amortization	0	0
Total operating expenses	0	0
Operating income	35	(1,038)
Other (income) expense
Interest income	34,762	27,117
Interest expense	(34,762)	(27,117)
Loss on extinguishment of debt	0
Equity in (income) loss of subsidiaries	43,711	25,618
Total other expense	43,711	25,618
Income before income taxes	(43,676)	(26,656)
Provision for income taxes	0	0
Net income	(43,676)	(26,656)
Comprehensive income, net of tax:
Currency translation adjustments	1,215	(8,178)
Total other comprehensive income (loss)	1,215	(8,178)
Comprehensive income	$ (42,461)	$ (34,834)

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	$ 21,598	$ 21,318	$ 15,675	$ 28,331
Accounts receivable, net	85,576	87,858
Inventories	74,077	74,000
Deferred income tax assets	7,918	8,097
Prepaid expenses and other current assets	11,890	10,434
Total current assets	201,059	201,707
Property and equipment, net	13,154	13,744
Goodwill	290,867	290,651
Intangible assets, net	2,129,860	2,134,700
Other long-term assets	1,562	1,165
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,636,502	2,641,967
Current liabilities
Current portion of long-term debt	8,525	0
Accounts payable	47,170	46,115
Accrued interest payable	9,359	11,974
Other accrued liabilities	36,738	40,948
Total current liabilities	101,792	99,037
Long-term debt
Principal amount	1,540,075	1,593,600
Less unamortized debt costs	(33,534)	(32,327)
Long-term debt, net	1,506,541	1,561,273
Deferred income tax liabilities	362,928	351,569
Other long-term liabilities	2,517	2,464
Intercompany payables	0	0
Total Liabilities	1,973,778	2,014,343
Stockholders' Equity
Common stock	530	525
Additional paid-in capital	437,554	426,584
Treasury stock, at cost	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(23,817)	(23,412)
Retained earnings (accumulated deficit)	253,578	227,405
Total Stockholders' Equity	662,724	627,624
Total Liabilities and Stockholders' Equity	2,636,502	2,641,967
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	10,832	11,387	10,919	24,644
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	311	452
Prepaid expenses and other current assets	7,883	5,731
Total current assets	19,026	17,570
Property and equipment, net	10,301	10,726
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,215,771	1,210,017
Investment in subsidiary	1,569,115	1,545,575
Total Assets	2,814,213	2,783,888
Current liabilities
Current portion of long-term debt	0
Accounts payable	2,846	1,959
Accrued interest payable	0	0
Other accrued liabilities	4,710	10,378
Total current liabilities	7,556	12,337
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,143,933	2,143,927
Total Liabilities	2,151,489	2,156,264
Stockholders' Equity
Common stock	530	525
Additional paid-in capital	437,554	426,584
Treasury stock, at cost	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(23,817)	(23,412)
Retained earnings (accumulated deficit)	253,578	227,405
Total Stockholders' Equity	662,724	627,624
Total Liabilities and Stockholders' Equity	2,814,213	2,783,888
Prestige Brands, Inc., the issuer or the borrower
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	11,368	14,539
Inventories	7,492	8,667
Deferred income tax assets	705	674
Prepaid expenses and other current assets	243	141
Total current assets	19,808	24,021
Property and equipment, net	163	175
Goodwill	66,007	66,007
Intangible assets, net	192,191	192,325
Other long-term assets	1,562	1,165
Intercompany receivables	2,572,637	2,607,054
Investment in subsidiary	1,245,085	1,228,535
Total Assets	4,097,453	4,119,282
Current liabilities
Current portion of long-term debt	8,525
Accounts payable	6,504	6,829
Accrued interest payable	9,359	11,974
Other accrued liabilities	1,400	1,153
Total current liabilities	25,788	19,956
Long-term debt
Principal amount	1,540,075	1,593,600
Less unamortized debt costs	(33,534)	(32,327)
Long-term debt, net	1,506,541	1,561,273
Deferred income tax liabilities	59,464	59,038
Other long-term liabilities	0	0
Intercompany payables	1,003,970	1,001,219
Total Liabilities	2,595,763	2,641,486
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,280,948	1,280,948
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(23,817)	(23,412)
Retained earnings (accumulated deficit)	244,559	220,260
Total Stockholders' Equity	1,501,690	1,477,796
Total Liabilities and Stockholders' Equity	4,097,453	4,119,282
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	66,016	66,523
Inventories	61,651	60,297
Deferred income tax assets	6,567	6,497
Prepaid expenses and other current assets	3,016	3,804
Total current assets	137,250	137,121
Property and equipment, net	2,291	2,207
Goodwill	204,510	204,205
Intangible assets, net	1,850,501	1,854,798
Other long-term assets	0	0
Intercompany receivables	695,741	668,169
Investment in subsidiary	67,970	65,564
Total Assets	2,958,263	2,932,064
Current liabilities
Current portion of long-term debt	0
Accounts payable	33,871	32,898
Accrued interest payable	0	0
Other accrued liabilities	27,116	25,795
Total current liabilities	60,987	58,693
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	303,440	292,504
Other long-term liabilities	2,333	2,293
Intercompany payables	1,275,240	1,279,833
Total Liabilities	1,642,000	1,633,323
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,131,578	1,131,578
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(23,817)	(23,412)
Retained earnings (accumulated deficit)	208,502	190,575
Total Stockholders' Equity	1,316,263	1,298,741
Total Liabilities and Stockholders' Equity	2,958,263	2,932,064
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	10,766	9,931	4,756	3,687
Accounts receivable, net	8,192	6,796
Inventories	6,045	6,182
Deferred income tax assets	335	474
Prepaid expenses and other current assets	748	758
Total current assets	26,086	24,141
Property and equipment, net	399	636
Goodwill	20,350	20,439
Intangible assets, net	87,168	87,577
Other long-term assets	0	0
Intercompany receivables	9,174	8,764
Investment in subsidiary	0	0
Total Assets	143,177	141,557
Current liabilities
Current portion of long-term debt	0
Accounts payable	3,949	4,429
Accrued interest payable	0	0
Other accrued liabilities	3,512	3,622
Total current liabilities	7,461	8,051
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	24	27
Other long-term liabilities	184	171
Intercompany payables	70,180	69,025
Total Liabilities	77,849	77,274
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	74,031	74,031
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(23,817)	(23,412)
Retained earnings (accumulated deficit)	15,114	13,664
Total Stockholders' Equity	65,328	64,283
Total Liabilities and Stockholders' Equity	143,177	141,557
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories	(1,111)	(1,146)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(1,111)	(1,146)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(4,493,323)	(4,494,004)
Investment in subsidiary	(2,882,170)	(2,839,674)
Total Assets	(7,376,604)	(7,334,824)
Current liabilities
Current portion of long-term debt	0
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(4,493,323)	(4,494,004)
Total Liabilities	(4,493,323)	(4,494,004)
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	(2,486,557)	(2,486,557)
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	71,451	70,236
Retained earnings (accumulated deficit)	(468,175)	(424,499)
Total Stockholders' Equity	(2,883,281)	(2,840,820)
Total Liabilities and Stockholders' Equity	$ (7,376,604)	$ (7,334,824)

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Activities
Net income (loss)	$ 26,173	$ 16,732
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	5,720	2,961
Gain on sale of asset	(36)	0
Deferred income taxes	11,536	7,140
Amortization of debt origination costs	2,138	995
Stock-based compensation costs	3,047	1,858
Loss on extinguishment of debt	451	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,578	6,956
Inventories	(211)	1,540
Prepaid expenses and other current assets	(1,522)	(2,203)
Accounts payable	783	(3,096)
Accrued liabilities	(7,136)	(3,212)
Net cash provided by (used in) operating activities	43,521	29,671
Investing Activities
Purchases of property and equipment	(780)	(496)
Proceeds from sale of business	344
Acquisition of Care Pharmaceuticals, less cash acquired		(77,991)
Intercompany activity, net		0
Net cash used in investing activities	(436)	(78,487)
Financing Activities
Term loan repayments	(25,000)	0
Borrowings under revolving credit agreement	15,000	65,000
Repayments under revolving credit agreement	(35,000)	(30,000)
Payments of debt origination costs	(4,172)	(74)
Proceeds from exercise of stock options	6,328	1,294
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,600	950
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,171)
Intercompany activity, net	0	0
Net cash (used in) provided by financing activities	(42,887)	36,056
Effects of exchange rate changes on cash and cash equivalents	82	104
Increase (decrease) in cash and cash equivalents	280	(12,656)
Cash and cash equivalents - beginning of period	21,318	28,331
Cash and cash equivalents - end of period	21,598	15,675
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	26,173	16,732
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	989	642
Gain on sale of asset	0
Deferred income taxes	141	(1)
Amortization of debt origination costs	0	0
Stock-based compensation costs	3,047	1,858
Loss on extinguishment of debt	0
Equity in income of subsidiaries	(25,306)	(15,679)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	467
Inventories	0	0
Prepaid expenses and other current assets	(2,152)	947
Accounts payable	861	(936)
Accrued liabilities	(5,668)	(4,800)
Net cash provided by (used in) operating activities	(1,915)	(770)
Investing Activities
Purchases of property and equipment	(648)	(385)
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash used in investing activities	(648)	(385)
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	6,328	1,294
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,600	950
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,171)
Intercompany activity, net	(4,277)	(13,700)
Net cash (used in) provided by financing activities	2,008	(12,570)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	(555)	(13,725)
Cash and cash equivalents - beginning of period	11,387	24,644
Cash and cash equivalents - end of period	10,832	10,919
Prestige Brands, Inc., the issuer or the borrower
Operating Activities
Net income (loss)	24,299	17,506
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	146	145
Gain on sale of asset	0
Deferred income taxes	395	892
Amortization of debt origination costs	2,138	995
Stock-based compensation costs	0	0
Loss on extinguishment of debt	451
Equity in income of subsidiaries	(16,955)	(10,898)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	3,171	(130)
Inventories	1,175	3,288
Prepaid expenses and other current assets	(102)	(920)
Accounts payable	(325)	(916)
Accrued liabilities	(2,368)	4,733
Net cash provided by (used in) operating activities	12,025	14,695
Investing Activities
Purchases of property and equipment	0	0
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		(77,991)
Net cash used in investing activities	0	(77,991)
Financing Activities
Term loan repayments	(25,000)
Borrowings under revolving credit agreement	15,000	65,000
Repayments under revolving credit agreement	(35,000)	(30,000)
Payments of debt origination costs	(4,172)	(74)
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	37,147	28,370
Net cash (used in) provided by financing activities	(12,025)	63,296
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	17,927	10,109
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	4,445	2,089
Gain on sale of asset	0
Deferred income taxes	10,866	6,330
Amortization of debt origination costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Equity in income of subsidiaries	(1,450)	959
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	735	8,941
Inventories	(1,457)	(2,822)
Prepaid expenses and other current assets	722	(1,706)
Accounts payable	880	(2,918)
Accrued liabilities	975	(5,663)
Net cash provided by (used in) operating activities	33,643	15,319
Investing Activities
Purchases of property and equipment	(27)	(11)
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash used in investing activities	(27)	(11)
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	(33,616)	(15,308)
Net cash (used in) provided by financing activities	(33,616)	(15,308)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	1,450	(959)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	140	85
Gain on sale of asset	(36)
Deferred income taxes	134	(81)
Amortization of debt origination costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(1,328)	(2,322)
Inventories	106	36
Prepaid expenses and other current assets	10	(524)
Accounts payable	(633)	1,674
Accrued liabilities	(75)	2,518
Net cash provided by (used in) operating activities	(232)	427
Investing Activities
Purchases of property and equipment	(105)	(100)
Proceeds from sale of business	344
Acquisition of Care Pharmaceuticals, less cash acquired		(77,991)
Intercompany activity, net		77,991
Net cash used in investing activities	239	(100)
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	746	638
Net cash (used in) provided by financing activities	746	638
Effects of exchange rate changes on cash and cash equivalents	82	104
Increase (decrease) in cash and cash equivalents	835	1,069
Cash and cash equivalents - beginning of period	9,931	3,687
Cash and cash equivalents - end of period	10,766	4,756
Eliminations
Operating Activities
Net income (loss)	(43,676)	(26,656)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	0	0
Gain on sale of asset	0
Deferred income taxes	0	0
Amortization of debt origination costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Equity in income of subsidiaries	43,711	25,618
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0
Inventories	(35)	1,038
Prepaid expenses and other current assets	0	0
Accounts payable	0	0
Accrued liabilities	0	0
Net cash provided by (used in) operating activities	0	0
Investing Activities
Purchases of property and equipment	0	0
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash used in investing activities	0	0
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	0	0
Net cash (used in) provided by financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$ 0	$ 0

Subsequent Events (Details) (Restricted Stock Units (RSUs))	0 Months Ended	3 Months Ended		0 Months Ended
	May 11, 2015	Jun. 30, 2015	Jun. 30, 2014	Aug. 04, 2015 Subsequent Event
Subsequent Event [Line Items]
Granted in period (in shares)	185,904	243,800	96,600	2,075
Number of common shares into which each RSU may be converted (in shares)				1
Period following director's term in which RSUs may be settled				6 months

Subsequent Events Subsequent Events	3 Months Ended
Subsequent Events Subsequent Events	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Pursuant to the Plan, each of the independent members of the Board of Directors received a grant of 2,075 restricted stock units on August 4, 2015. The restricted stock units vest on August 4, 2016 and shall be settled by delivery to the director of one share of common stock of the Company for each vested restricted stock unit promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

Business and Basis of Presentation (Property and Equipment) (Details)	3 Months Ended
	Jun. 30, 2015
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Presentation (Intangible Assets) (Details)	3 Months Ended
	Jun. 30, 2015
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Business and Basis of Presentation (Debt Issuance Costs) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015
Debt Instrument [Line Items]
Other long-term assets	$ (1,562)	$ (1,165)
Adjustments for new accounting pronouncement
Debt Instrument [Line Items]
Other long-term assets		$ 27,400

Earnings Per Share (Antidilutive Securities) (Details) (Outstanding Stock Awards) In Millions, unless otherwise specified	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	0.2	0.3